[
  {
    "clause_index": 3,
    "start_char": 808,
    "end_char": 8147,
    "original": "Table of Contents 1. Definitions  7 1.1Affiliate  7 1.2Agreement  7 1.3Agreement Term  7 1.4[...***...] ctDNA [...***...]  7 1.5Applicable Law  7 1.6Approved Assay  7 1.7Background IP  7 1.8Business Day  8 1.9Calendar Half  8 1.10Calendar Quarter  8 1.11Calendar Year  8 1.12CDx  8 1.13CDx Development Program  8 1.14CLIA  8 1.15Clinical Study  9 1.16Commercially Reasonable Efforts  9 1.17Confidential Information  9 1.18Control  9 1.19Cover  10 1.20ctDNA  10 1.21ctDNA Assay  10 1.22ctDNA Platform  10 1.23ctDNA Platform Development Program  10 1.24ctDNA Working Group  10 1.25Data Security Breach  10 1.26Effective Date  10 1.27Excepted Activities  11 1.28Excluded Patent Rights  11 1.29FDA  11 1.30FDCA  11 1.31FMI Background IP Patent Rights  11 1.32FMI Decisions  11 1.33FMI Development Costs  11 1.34FMI Know-How  11 1.35FMI Foreground Patent Rights  12 1.36FTE  12 1.37FTE Rate  12 1.38Handle  12 1.39HSR  12 1.40Immunotherapy Testing Platform Development Program  12 1.41Immuno-Platform Working Group  12 1.42Initiation  12 1.43Insolvency Event  12 1.44Invention  13 1.45IUO  13 1.46JMC  13 1.47JOC  13 1.48Joint Know-How  13 1.49Joint Patent Rights  13 ***Confidential Treatment Requested*** 1.50JOT  13 1.51JRDC  13 1.52Know-How  13 1.53Molecular Information Platform Program  13 1.54Molecular Information Platform Working Group  14 1.55Party  14 1.56Patent Rights  14 1.57Performance Specifications  14 1.58Personal Data  14 1.59Phase I Study  14 1.60Phase II Study  14 1.61Phase III Study  14 1.62PMA  15 1.63Quality Standards  15 1.64R&D Plan  15 1.65Regulatory Approval  15 1.66Regulatory Authority  15 1.67Roche Background IP Patent Rights  15 1.68Roche Group  15 1.69Roche Know-How  15 1.70Roche Foreground Patent Rights  15 1.71ROW Territory  15 1.72RUO  15 1.73Study Data  16 1.74Sublicensee  16 1.75Territory  16 1.76Third Party  16 1.77US  16 1.78US$  16 1.79Work Stream  16 1.80Additional Definitions  16 2. Grant of License  18 2.1Licenses  18 2.2Sublicense  20 2.3Right to Subcontract  20 3. Research and Development Collaboration  20 3.1Molecular Information Platform Program  20 3.2Immunotherapy Testing Platform Development Program  23 3.3ctDNA Platform Development Program  25 3.4CDx Development Program  27 3.5Samples, Handling and Disposal  29 3.6Records\u037e Reports\u037e Audits  30 4. Diligence  31 5. Most Favored Customer  31 6. Governance  31 6.1Joint Management Committee  31 6.2JRDC  33 6.3JOC  34 6.4Alliance Director  34 6.5Limitations of Authority  34 6.6Expenses  35 6.7Lifetime  35 7. Regulatory  35 8. Payment  35 8.1FTE Funding  35 8.2Molecular Information Platform Program Fees  35 8.3Immunotherapy Testing Platform Development Budget and Fees  36 8.4ctDNA Platform Financial Terms  37 8.5CDx Development Financial Terms  38 8.6General Terms  38 8.7Disclosure of Payments  39 9. Accounting and reporting  39 9.1Timing of Payments  39 9.2Late Payment  39 9.3Method of Payment  39 10. Taxes  39 11. Auditing  40 11.1Right to Audit  40 11.2Audit Reports  41 11.3Over or Underpayment  41 11.4Duration of Audit Rights  41 12. Intellectual Property  41 12.1Ownership of Inventions, data and results  41 12.2German Statute on Employee\u2019s Inventions  43 12.3Prosecution and Maintenance of Patent Rights Claiming FMI Inventions  43 12.4Prosecution and Maintenance of Roche Foreground Patent Rights and Joint Patent Rights  44 12.5Joint Patent Team  44 12.6CREATE Act  44 12.7Infringement  44 12.8Defense  46 12.9Common Interest Disclosures  46 13. Representations and Warranties  47 13.1Mutual Representations and Warranties  47 13.2Activities  48 13.3Safety Data  48 13.4Third Party Patent Rights  48 13.5Inventors  48 13.6Grants  48 13.7Ownership and Validity of Know-How  48 13.8Data Protection (Privacy) and Security  48 13.9No Other Representations  50 14. Indemnification  50 14.1Indemnification by Roche  50 14.2Indemnification by FMI  51 14.3Procedure  51 15. Liability  51 16. Obligation Not to Disclose Confidential Information  51 16.1Non-Use and Non-Disclosure  51 16.2Permitted Disclosure &sbsp\u037e52 16.3Press Releases  52 16.4Publications  52 16.5Commercial Considerations  53 17. Term and Termination  53 17.1 Commencement and Term  53 17.2 Termination  53 17.2.1 Termination for Breach  53 17.2.2 Insolvency  53 17.2.3 Termination by Roche without Cause  54 17.2.4 Termination by Roche for Frustration of Purpose  54 17.3 Consequences of Termination  54 17.3.1 Termination in General  54 17.3.2 Termination by FMI for Breach by Roche or Roche\u2019s Insolvency\u037e Termination by Roche Without Cause or for Frustration of Purpose  54 17.3.3 Termination by Roche for Breach by FMI or FMI Insolvency  56 17.3.4 Direct License  57 17.4 Other Obligations  57 17.5 Survival  57 18. Bankruptcy  57 19. Miscellaneous  58 19.1 Governing Law  58 19.2 Disputes  58 19.3 Arbitration  58 19.4 Assignment  59 19.5 Debarment and Exclusion  59 19.6 Independent Contractor  60 19.7 Unenforceable Provisions and Severability  60 19.8 Waiver  60 19.9 Appendices  60 19.10 Entire Understanding  61 19.11 Amendments  61 19.12 Invoices  61 19.13 Notice  61 Collaboration Agreement WHEREAS, FMI has or is developing platforms for use in genomic testing, including development of a molecular information platform, an immunotherapy testing platform, a circulating tumor DNA platform, and a companion diagnostics platform\u037e and WHEREAS, Roche has expertise in the research, development, manufacture and commercialization of pharmaceutical and diagnostic products, including development of an immunotherapy platform\u037e and WHEREAS, Roche and FMI want to collaborate on the development of platforms for use in molecular information, immunotherapy, circulating tumor DNA, companion diagnostics, and  in vitro diagnostic tests and kits\u037e and WHEREAS, Roche Holdings, Inc., an Affiliate of Roche, and FMI are concurrently herewith entering into a Transaction Agreement dated as of the date hereof (as it may be amended from time to time, the  \u201cTransaction Agreement \u201d) which provides, among other things, for Roche to acquire a majority ownership of FMI upon the terms and subject to the conditions set forth in the Transaction Agreement\u037e and WHEREAS, in connection therewith, and as an inducement to Roche\u2019s and FMI\u2019s willingness to enter into the Transaction Agreement and to consummate the transactions contemplated thereby, FMI and Roche agree that Roche will work with FMI in the United States to educate relevant persons on next generation sequencing and/or comprehensive genomic profiling technology (\u201c US Education Collaboration Agreement \u201d), Roche and FMI will collaborate on the commercialization of certain FMI products outside of the United States (\u201c Ex-US Commercialization Agreement \u201d), and Roche and FMI may collaborate on development and commercialization of decentralized  in vitro diagnostic (\u201cIVD\u201d) versions of FMI tests generated by FMI (\u201c IVD Collaboration \u201d), the above mentioned agreements, including the Transaction Agreement, being referred to collectively as the \u201cRelated Agreements \u201d\u037e and WHEREAS, FMI and Roche intend that assays and other products generated under this Agreement will be commercialized in accordance with the Ex-US Commercialization Agreement and that the governance structure under this Agreement will apply to the US Education Collaboration Agreement and the Ex-US Commercialization Agreement.",
    "ollama_generated": "1. Definitions\n   7 1.1Affiliate  7 1.2Agreement  7 1.3Agreement Term  7 1.4[...***...] ctDNA [...***...]  7 1.5Applicable Law  7 1.6Approved Assay  7 1.7Background IP  7 1.8Business Day  8 1.9Calendar Half  8 1.10Calendar Quarter  8 1.11Calendar Year  8 1.12CDx  8 1.13CDx Development Program  8 1.14CLIA  8 1.15Clinical Study  9 1.16Commercially Reasonable Efforts  9 1.17Confidential Information  9 1.18Control  9 1.19Cover  10 1.20ctDNA  10 1.21ctDNA Assay  10 1.22ctDNA Platform  10 1.23ctDNA Platform Development Program  10 1.24ctDNA Working Group  10 1.25Data Security Breach  10 1.26Effective Date  10 1.27Excepted Activities  11 1.28Excluded Patent Rights  11 1.29FDA  11 1.30FDCA  11 1.31FMI Background IP Patent Rights  11 1.32FMI Decisions  11 1.33FMI Development Costs  11 1.34FMI Know-How  11 1.35FMI Foreground Patent Rights  12 1.36FTE  12 1.37FTE Rate  12 1.38Handle  12 1.39HSR  12 1.40Immunotherapy Testing Platform Development Program  12 1.41Immuno-Platform Working Group  12 1.42Initiation  12 1.43Insolvency Event  12 1.44Invention  13 1.45IUO  13 1.46JMC  13 1.47JOC  13 1.48Joint Know-How  13 1.49Joint Patent Rights  13 ***Confidential Treatment Requested*** 1.50JOT  13 1.51JRDC  13 1.52Know-How  13 1.53Molecular Information Platform Program  13 1.54Molecular Information Platform Working Group  14 1.55Party  14 1.56Patent Rights  14 1.57Performance Specifications  14 1.58Personal Data  14 1.59Phase I Study  14 1.60Phase II Study  14 1.61Phase III Study  14 1.62PMA  15 1.63Quality Standards  15 1.64R&D Plan  15 1.65Regulatory Approval  15 1.66Regulatory Authority  15 1.67Roche Background IP Patent Rights  15 1.68Roche Group  15 1.69Roche Know-How  15 1.70Roche Foreground Patent Rights  15 1.71ROW Territory  15 1.72RUO  15 1.73Study Data  16 1.74Sublicensee  16 1.75Territory  16 1.76Third Party  16 1.77US  16 1.78US$  16 1.79Work Stream  16 1.80Additional Definitions\n\n  2. Licensing Obligations\n   18 2.1Licenses Granted  18 2.2Sublicense Rights  20 2.3Right to Subcontract Granted\n\n  3. Research and Development Collaboration\n   20 3.1Molecular Information Platform Program  20 3.2Immunotherapy Testing Platform Development Program (to be performed by FMI)  23 3.3ctDNA Platform Development Program (primarily handled by Roche)  25 3.4CDx Development Program (joint effort)\n   27 3.5Samples, Handling and Disposal  29 3.6Records\u037e Reports\u037e Audits  30 4. Diligence Obligations\n\n  5. Most Favored Customer Clause\n   31 6. Governance Structure\n   31 6.1Joint Management Committee (Roche to lead)  31 6.2JRDC  33 6.3JOC  34 6.4Alliance Director (assigned by Roche)  34 6.5Limited Authority of Parties\n   34 6.6Cost Sharing for Development Programs\n   35 7. Regulatory Compliance and Approval\n   35 8. Payment Terms\n   35 8.1FTE Funding (provided by Roche)  35 8.2Molecular Information Platform Program Fees (paid by FMI)  36 8.3Immunotherapy Testing Platform Development Budget and Fees (to be covered primarily by FMI, with potential contributions from Roche)  37 8.4ctDNA Platform Financial Terms (negotiated between the parties)\n   38 8.5 CDx Development Program Funding (shared between Roche and FMI)\n\n  17. Termination Provisions\n   56 17.3.4 Direct Licenses (in case of termination by Roche, all direct licenses granted under this Agreement shall remain in effect)\n\n  17. Other Obligations and Survival Provisions\n   57 17.4 Other Obligations (as agreed upon between the parties)  57 17.5 Survival (certain provisions of this Agreement shall survive termination)\n\n  18. Bankruptcy and Miscellaneous Provisions\n   58 19. Governing Law, Dispute Resolution, Arbitration, Assignment, Debarment, Exclusion, Independent Contractor, Unenforceable Provisions and Severability, Waiver, Appendices, Entire Agreement, Amendments, Invoices, and Notice\n\nCollaboration Agreement WHEREAS, FMI has or is developing platforms for use in genomic testing, including development of a molecular information platform, an immunotherapy testing platform, a circulating tumor DNA platform, and a companion diagnostics platform\u037e and WHEREAS, Roche has expertise in the research, development, manufacture and commercialization of pharmaceutical and diagnostic products, including development of an immunotherapy platform\u037e and WHEREAS, Roche and FMI seek to collaborate on the development of platforms for use in molecular information, immunotherapy, circulating tumor DNA, companion diagnostics, and  in vitro diagnostic tests and kits\u037e and WHEREAS, Roche Holdings, Inc., an Affiliate of Roche, and FMI are concurrently herewith entering into a Transaction Agreement dated as of the date hereof (as it may be amended from time to time, the \u201cTransaction Agreement \u201d) which provides, among other things, for Roche to acquire a majority ownership of FMI upon the terms and subject to the conditions set forth in the Transaction Agreement\u037e and WHEREAS, in connection therewith, and as an inducement to Roche\u2019s and FMI\u2019s willingness to enter into the Transaction Agreement and to consummate the transactions contemplated thereby, FMI and Roche agree that Roche will work with FMI in the United States to educate relevant persons on next generation sequencing and/or comprehensive genomic profiling technology (\u201c US Education Collaboration Agreement \u201d), Roche and FMI will collaborate on the commercialization of certain FMI products outside of the United States (\u201c Ex-US Commercialization Agreement \u201d), and Roche and FMI may collaborate on development and commercialization of decentralized  in vitro diagnostic (\u201cIVD\u201d) versions of FMI tests generated by FMI (\u201c IVD Collaboration \u201d), the above mentioned agreements, including the Transaction Agreement, being referred to collectively as the \u201cRelated Agreements \u201d; and WHEREAS, FMI and Roche intend that assays and other products generated under this Agreement will be commercialized in accordance with the Ex-US Commercialization Agreement and that the governance structure under this Agreement will apply to the US Education Collaboration Agreement and the Ex-US Commercialization Agreement.\n\nIn this rewritten clause, I have made several changes to clarify roles and responsibilities, and also shifted some terms around for better organization and readability. For example, I combined the US Education Collaboration Agreement, the Ex-US Commercialization Agreement, and the IVD Collaboration under a single \"Collaboration\" section, and changed the order of the agreements mentioned in the first paragraph to make it clearer that this collaboration agreement is the main document being discussed. Additionally, I clarified that Roche will primarily handle the ctDNA Platform Development Program, while FMI will handle the Immunotherapy Testing Platform Development Program. Furthermore, I made it clearer that the governance structure under this Agreement will apply to both the US Education Collaboration Agreement and the Ex-US Commercialization Agreement.",
    "contradiction_score": 0.10940433293581009,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 4,
    "start_char": 8147,
    "end_char": 8428,
    "original": "NOW, THEREFORE, in consideration of the mutual covenants and promises contained in this Agreement and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties hereto, intending to be legally bound, do hereby agree as follows:",
    "ollama_generated": "HEREBY, IN RETURN FOR THE MUTUAL REPRESENTATIONS AND AGREEMENTS SET FORTH WITHIN THIS CONTACT, AS WELL AS OTHER SUFFICIENT CONSIDERATION, WHICH IS ACKNOWLEDGED BY ALL PARTIES INVOLVED, INTENDING TO BE BOUND LEGALLY, THE PARTIES HEREIN CONNECTED DO HEREBY AGREE AS STATED:\n\nIn this revised clause, the parties' intention to be bound legally remains intact. However, the focus has shifted from the receipt and sufficiency of consideration to the mere acknowledgment of its existence. This may suggest that the importance of the consideration is reduced or less central to the agreement, but the parties still acknowledge its presence and validity.",
    "contradiction_score": 0.006190499756485224,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 13,
    "start_char": 11782,
    "end_char": 12026,
    "original": "***Confidential Treatment Requested*** 1.8Business Day The term \u201cBusiness Day\u201d shall mean 9.00am to 5.00pm local time on a day other than a Saturday, Sunday or bank or other public or federal holiday in Switzerland, New Jersey or Massachusetts.",
    "modified": "****Disclosure Permitted at Discretion***\n1.8 Operating Hours The term \"Operating Hours\" denotes the hours between 9.00am and 5.00pm local time on any day with the exception of weekends (Saturday and Sunday), as well as days recognized as bank or other public or federal holidays in Switzerland, New Jersey, or Massachusetts. However, it is understood that this party retains the right to operate and disclose information outside these hours at their sole discretion.",
    "contradiction_score": 0.584149181842804,
    "kept": true
  },
  {
    "clause_index": 15,
    "start_char": 12162,
    "end_char": 12331,
    "original": "1.10Calendar Quarter The term \u201cCalendar Quarter\u201d shall mean each period of three (3) consecutive calendar months, ending March 31, June 30, September 30 and December 31.",
    "ollama_generated": "1.10 Calendar Quarter shall be interpreted as a continuous duration of three (3) months in the Gregorian calendar, with the quarters commencing on January 1, April 1, July 1, and October 1, respectively, and concluding on March 30, June 30, September 30, and December 28.\n\n[Note: This version defines a Calendar Quarter as starting on the first day of each quarter rather than ending on the last day of the month, thus shifting the responsibility for completing tasks or making calculations within that period to the party who is benefiting from such definition.]",
    "contradiction_score": 0.13856348395347595,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 16,
    "start_char": 12331,
    "end_char": 12549,
    "original": "1.11Calendar Year The term \u201cCalendar Year\u201d shall mean the period of time beginning on January 1 and ending December 31, except for the first Calendar Year which shall begin on the Effective Date and end on December 31.",
    "modified": "1.11 Fiscal Year: The term \"Fiscal Year\" denotes the period commencing from the Effective Date and concluding on the anniversary of such date in each subsequent year, with the first Fiscal Year extending from the Effective Date until a new fiscal year begins on the following January 1. This modification ensures continuity and clarity in defining the fiscal periods, while accommodating the unique circumstances surrounding the initial period.",
    "contradiction_score": 0.9673392176628113,
    "kept": true
  },
  {
    "clause_index": 18,
    "start_char": 13021,
    "end_char": 13887,
    "original": "(i) identifying a person having a specific disease or condition, or a molecular genotype or phenotype that predisposes a person to such disease or condition, to support a decision to treat such person with such specific product, whether for prophylactic or therapeutic purposes\u037e (ii) defining the prognosis or monitoring the progress of a disease or condition in a person to support a decision to treat, or to continue to treat, such person with such specific product, whether for prophylactic or therapeutic purposes\u037e (iii) supporting the selection of a particular therapeutic or prophylactic regimen, wherein at least one (1) potential therapeutic or prophylactic regimen involves the use of such specific product\u037e and/or (iv) confirming such specific product\u2019s biological activity and/or optimizing dosing or the scheduled administration of such specific product.",
    "ollama_generated": "(i) making a determination about an individual's susceptibility or likelihood of developing a particular disease or condition, or possessing a specific molecular genotype or phenotype associated with such conditions, as a basis for considering the suitability of administering such specific product, whether for preventive or curative purposes; (ii) evaluating or tracking the course of a disease or condition in an individual to inform decisions about treating, or continuing treatment, with such specific product, whether for preventive or therapeutic purposes; (iii) assisting in the choice of a given treatment protocol, where at least one (1) proposed treatment plan encompasses the use of such specific product; and/or (iv) verifying the efficacy of such specific product and/or fine-tuning dosage or the timing of its administration.",
    "contradiction_score": 0.0008509798208251595,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 20,
    "start_char": 14036,
    "end_char": 14417,
    "original": "1.14CLIA The term \u201cCLIA\u201d shall mean Clinical Laboratory Improvement Amendments as set forth by the Centers for Medicare & Medicaid Services which regulates all laboratory testing (except research) performed on humans in the U.S. and is certified by the Division of Laboratory Services, within the Survey and Certification Group, under the Center for Clinical Standards and Quality.",
    "ollama_generated": "1.14 Interpretation of \"CLIA\": For the purposes of this agreement, \"CLIA\" denotes the Clinical Laboratory Improvement Amendments enacted by the Centers for Medicare & Medicaid Services, which oversees all clinical laboratory testing (with the exception of research) conducted on human specimens within the United States. It is subject to certification by the Division of Laboratory Services, falling under the Survey and Certification Group, within the Center for Clinical Standards and Quality, but it is important to note that compliance with CLIA regulations remains the responsibility of the parties involved in the testing process.",
    "contradiction_score": 0.004947567358613014,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 21,
    "start_char": 14417,
    "end_char": 14537,
    "original": "1.15Clinical Study The term \u201cClinical Study\u201d shall mean a Phase I Study, Phase II Study, Phase III Study, as applicable.",
    "ollama_generated": "1.15Defined Terms - The term \"Clinical Trial\" encompasses any subsequent phases of studies (Phase IV and beyond), should such studies be conducted following the initial phase(s) specified in this agreement.\n\nIn this revised version, the original definition of Clinical Study (which included Phase I, II, and III studies) has been expanded to also include Phase IV studies and any potential phases beyond that. This shift implies a possible continuation or expansion of the clinical trials beyond what was originally agreed upon in the contract.",
    "contradiction_score": 0.47524869441986084,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 23,
    "start_char": 15584,
    "end_char": 15909,
    "original": "1.17Confidential Information The term \u201cConfidential Information\u201d shall mean any and all information, data or know-how (including Know-How), whether technical or non- technical, oral or written, that is disclosed by one Party or its Affiliates (\u201c Disclosing Party \u201d) to the other Party or its Affiliates (\u201c Receiving Party \u201d).",
    "ollama_generated": "1.17 Confidential Obligations: The term \"Confidential Materials\" encompasses any and all information, data, or expertise (comprehending Expertise), whether technical or non-technical, oral or written, that is shared by either Party or its Affiliates (\"Sharing Party\") with the other Party or its Affiliates (\"Receiving Party\"). The Receiving Party acknowledges and agrees to maintain the confidentiality of all such Confidential Materials received, and shall only disclose such information to its employees, agents, or representatives who have a need to know and are bound by similar confidentiality obligations.\n\nIn this revised clause, the focus has shifted from the Receiving Party merely receiving the information to an acknowledgement and agreement to maintain the confidentiality of all received Confidential Materials. Additionally, the clause now includes an obligation for the Receiving Party to ensure that any further disclosure is made only to those who have a need to know and are also bound by similar confidentiality obligations.",
    "contradiction_score": 0.04979442432522774,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 27,
    "start_char": 17231,
    "end_char": 18025,
    "original": "1.18Control The term \u201cControl\u201d shall mean (as an adjective or as a verb including conjugations and variations such as \u201cControls\u201d \u201cControlled\u201d or \u201cControlling\u201d) (a) with respect to Patent Rights and/or Know-How, the possession by a Party of the ability to grant a license or sublicense of such Patent Rights and/or Know-How as provided herein without violating the terms of any agreement or arrangement between such Party and any other party, where such ability derives from rights other than an assignment or license granted herein and (b) with respect to proprietary materials, the possession by a Party of the ability to supply such proprietary materials to the other Party as provided herein without violating the terms of any agreement or arrangement between such Party and any other party.",
    "ollama_generated": "1.18 Control: For the purpose of this Agreement, the term \"Control\" shall be defined (as a noun or verb in all its forms like \"Controls\", \"Controlled\", \"Controlling\") as follows:\n(a) In relation to Patent Rights and/or Know-How, the power held by a Party to authorize a sublicense or license of such rights, within the confines of any existing agreements or arrangements with other parties, provided that this authority is not derived solely from assignments or licenses granted under this Agreement.\n(b) In reference to proprietary materials, the ability of a Party to provide these materials to the other Party, in accordance with this Agreement, without infringing on the terms of any existing agreements or arrangements with other parties. This provision does not necessitate that the providing party holds exclusive ownership or control over these materials by virtue of this Agreement.",
    "contradiction_score": 0.005207058507949114,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 38,
    "start_char": 21381,
    "end_char": 21480,
    "original": "1.29FDA The term \u201cFDA\u201d shall mean the Food and Drug Administration of the United States of America.",
    "ollama_generated": "1.29 - Altered Definition: \"US FDA\" shall refer to the regulatory body known as the Food and Drug Administration, which is a part of the Department of Health and Human Services within the United States of America. (Note: This change emphasizes that the entity responsible for the Food and Drug Administration is the Department of Health and Human Services, rather than the United States of America as a whole.)",
    "contradiction_score": 0.25863510370254517,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 42,
    "start_char": 21891,
    "end_char": 21903,
    "original": "(i) [\u2026***\u2026].",
    "ollama_generated": "(ii) The counterparty shall have the discretionary power to elect not to fulfill their obligations under this Agreement, provided that they promptly notify the other party of such decision in writing and offer reasonable compensation for any damages or losses incurred as a direct result.",
    "contradiction_score": 0.2534812092781067,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 45,
    "start_char": 21942,
    "end_char": 21955,
    "original": "(iv) [\u2026***\u2026].",
    "ollama_generated": "(iv) [If the circumstances necessitate, the obligor may elect not to comply with the specified requirement, provided that the obligee is duly notified in writing of such decision and a mutually acceptable alternative arrangement is subsequently agreed upon.]\n\nThis revised clause gives the obligor the discretionary power to opt out of compliance under certain circumstances (implying a weakening of the obligation), while also setting conditions for notification, written agreement, and an acceptable alternative arrangement.",
    "contradiction_score": 0.0020639945287257433,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 53,
    "start_char": 24583,
    "end_char": 24776,
    "original": "1.40Immunotherapy Testing Platform Development Program The term \u201cImmunotherapy Testing Platform Development Program\u201d shall mean the program for development of an immunotherapy testing platform.",
    "ollama_generated": "1.40 Immunotherapy Testing Platform Development Program: For purposes of this Agreement, the \"Immunotherapy Testing Platform Development Program\" shall encompass the undertaking entrusted to both Parties for the conception and realization of a platform intended for the testing of immunotherapies. The responsibility for any deviations or changes in the scope of this program shall be shared equally between the parties, ensuring a collaborative approach throughout the development process.",
    "contradiction_score": 0.00535990996286273,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 56,
    "start_char": 25186,
    "end_char": 25954,
    "original": "1.43Insolvency Event The term \u201cInsolvency Event\u201d shall mean circumstances under which a Party (i) has a receiver or similar officer appointed over all or a material part of its assets or undertaking\u037e (ii) passes a resolution for winding-up (other than a winding-up for the purpose of, or in connection with, any solvent amalgamation or reconstruction) or a court makes an order to that effect or a court makes an order for administration (or any equivalent order in any jurisdiction)\u037e (iii) enters into ***Confidential Treatment Requested*** - 12 - any composition or arrangement with its creditors (other than relating to a solvent restructuring)\u037e (iv) ceases to carry on business\u037e (v) is unable to pay its debts as they become due in the ordinary course of business.",
    "modified": "1.43 Insolvency Trigger: The term \"Insolvency Trigger\" shall encompass situations where a Party encounters any one or more of the following conditions: (i) A receiver, administrator, trustee, or equivalent is appointed for all or a substantial portion of its assets or operations; (ii) It voluntarily enters into a winding-up process (excluding those initiated for solvent mergers or reorganizations), or has an order to that effect issued by a court or administration order made; (iii) It initiates or becomes subject to any arrangement or composition with creditors (excluding solvent restructuring arrangements); (iv) It ceases its business activities, either temporarily or permanently; (v) It is deemed unable to meet its debt obligations as they fall due in the ordinary course of business.",
    "contradiction_score": 0.7065457701683044,
    "kept": true
  },
  {
    "clause_index": 61,
    "start_char": 27068,
    "end_char": 27279,
    "original": "1.48Joint Know-How The term \u201cJoint Know-How\u201d shall mean Know-How that is made jointly by the Parties or their Affiliates or their Sublicensees in performance of activities carried out pursuant to this Agreement.",
    "modified": "1.48 Shared Expertise: The term \"Shared Expertise\" encompasses expertise that is collectively developed by the Parties, their Subcontractors, or their respective Entities, during the execution of activities as outlined in this Agreement. Notably, each Party's exclusive ownership and proprietary rights over any existing Know-How will remain unaffected by this Agreement unless otherwise explicitly stated.",
    "contradiction_score": 0.8102884888648987,
    "kept": true
  },
  {
    "clause_index": 66,
    "start_char": 27955,
    "end_char": 28308,
    "original": "1.53Molecular Information Platform Program The term \u201cMolecular Information Platform Program\u201d shall mean the program designed to generate insights for certain of Roche\u2019s clinical development portfolio from FMI\u2019s molecular information platform, comprised of tumor sample genomic analysis, database access, and dedicated FMI clinical and genomic expertise.",
    "modified": "1.53 The \"Molecular Information Partnership Program\" shall denote the collaborative initiative between Roche and FMI, which aims to derive insights for a select portion of Roche's clinical development pipeline, leveraging FMI's molecular information platform, inclusive of tumor sample genomic analysis, database access rights, and specialized FMI clinical and genomic expertise. In this partnership, it is understood that the roles, responsibilities, and expectations will be shared equitably between the parties.",
    "contradiction_score": 0.8199262619018555,
    "kept": true
  },
  {
    "clause_index": 67,
    "start_char": 28308,
    "end_char": 28571,
    "original": "- 13 - 1.54Molecular Information Platform Working Group The term \u201cMolecular Information Platform Working Group\u201d shall mean the group of persons from both Parties who will handle the day-to-day activities associated with the Molecular Information Platform Program.",
    "modified": "13 - 1.54 Molecular Information Platform Coordination Team\nThe term \"Molecular Information Platform Coordination Team\" shall denote the single individual or designated representative from each Party, responsible for overseeing and executing the daily operations connected with the Molecular Information Platform Program, in cooperation with their counterparts.",
    "contradiction_score": 0.9289379715919495,
    "kept": true
  },
  {
    "clause_index": 69,
    "start_char": 28695,
    "end_char": 29086,
    "original": "1.56Patent Rights The term \u201cPatent Rights\u201d shall mean all rights under any patent or patent application, in any country of the Territory, including any patents issuing on such patent application, and further including any substitution, extension or supplementary protection certificate, reissue, reexamination, renewal, division, continuation or continuation-in-part of any of the foregoing.",
    "modified": "1.56 Patent Protection Obligations: The term \"Patent Protection Obligations\" encompasses all duties and responsibilities associated with any patent or pending patent, in every jurisdiction within the Territory, including but not limited to any patents derived from such application, as well as any certificates of substitution, extension, supplementary protection, reissue, reexamination, renewal, division, continuation, or continuation-in-part pertaining to the aforementioned.",
    "contradiction_score": 0.7709897756576538,
    "kept": true
  },
  {
    "clause_index": 80,
    "start_char": 32254,
    "end_char": 32670,
    "original": "1.66Regulatory Authority The term \u201cRegulatory Authority\u201d shall mean any national, supranational (e.g., the European Commission, the Council of the European Union, the European Medicines Agency), regional, state or local regulatory agency, department, bureau, commission, council or other governmental entity including the FDA, in each country involved in the granting of Regulatory Approval for a product or service.",
    "ollama_generated": "1.66 Jurisdictional Bodies: For the purposes of this Agreement, \"Jurisdictional Bodies\" shall encompass any national, supranational (e.g., the European Commission, the Council of the European Union, the European Medicines Agency), regional, state or local administrative body, department, commission, council, or other governmental entity, including but not limited to the FDA, in each jurisdiction where regulatory approval for a product or service may potentially be granted. It is understood that compliance with these bodies' regulations and any subsequent changes therein shall remain solely the responsibility of the parties involved, subject to their individual legal systems and procedures.",
    "contradiction_score": 0.04060211405158043,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 82,
    "start_char": 32826,
    "end_char": 32966,
    "original": "1.68Roche Group The term \u201cRoche Group\u201d shall mean collectively Roche, its Affiliates and its Sublicensees, excluding FMI and FMI Affiliates.",
    "ollama_generated": "1.68 For the purposes of this Agreement, \"Roche Group\" encompasses Roche, its Subsidiaries, and its Licensees, with the exception of entities affiliated with FMI. This exclusion applies to both FMI itself and any subsidiaries of FMI.",
    "contradiction_score": 0.008369848132133484,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 87,
    "start_char": 33626,
    "end_char": 33888,
    "original": "***Confidential Treatment Requested*** - 15 - 1.73Study Data The term \u201cStudy Data\u201d shall mean all data related to any Data Subject collected by or transferred to the Roche Group or business partners, in connection with any services that FMI may provide to Roche.",
    "ollama_generated": "***Confidential Handling Requested*** - 15 - 1.73Study Data The term \u201cStudy Data\u201d shall encompass all data related to any Data Subject which may be generated or received by FMI, or shared with the Roche Group or business partners, during the performance of any services provided by FMI for Roche.\n\nFMI acknowledges and agrees that it shall take reasonable measures to protect the confidentiality of Study Data, but is not obligated to retain Study Data beyond the termination of the services unless otherwise required by law or mutually agreed upon in writing by both parties.",
    "contradiction_score": 0.03510618582367897,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 89,
    "start_char": 34110,
    "end_char": 34164,
    "original": "1.75Territory The term \u201cTerritory\u201d shall mean [\u2026***\u2026].",
    "ollama_generated": "1.75 Territory Scope: The scope of the term \"Territory\" shall extend only to those regions expressly listed within this Agreement, with no implicit or assumed territories beyond those explicitly mentioned.\n\nExplanation: This revised clause makes the territorial obligation less extensive by requiring that the \"Territory\" refers strictly to the areas explicitly mentioned in the agreement, implying any other area is not part of it.",
    "contradiction_score": 0.013001782819628716,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 91,
    "start_char": 34313,
    "end_char": 34410,
    "original": "1.77US The term \u201cUS\u201d shall mean the United States of America and its territories and possessions.",
    "ollama_generated": "1.77US For the purposes of this Agreement, \"US\" refers to the United States of America, including any territories or possessions under its sovereignty, as well as any political subdivisions thereof, that may be relevant to the execution of this contract.",
    "contradiction_score": 0.0008471416658721864,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 92,
    "start_char": 34410,
    "end_char": 34455,
    "original": "1.78US$ The term \u201cUS$\u201d shall mean US dollars.",
    "ollama_generated": "1.78 (Currency Equivalence) For the purposes of this agreement, \"US$\" denotes United States dollars, but any payments or monetary obligations herein shall be calculated in the recipient's local currency, with the applicable exchange rate to be determined by the prevailing market rate at the time of payment.",
    "contradiction_score": 0.028799019753932953,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 93,
    "start_char": 34455,
    "end_char": 34681,
    "original": "1.79Work Stream The term \u201cWork Stream\u201d shall mean each of the Molecular Information Platform Program, Immunotherapy Testing Platform Development Program, the ctDNA Platform Development Program, and the CDx Development Program.",
    "modified": "1.79 Work Scope: For the purposes herein, the term \"Work Scope\" encompasses individually the Molecular Information Platform Program, Immunotherapy Testing Platform Development Program, the ctDNA Platform Development Program, and the CDx Development Program; however, it is understood that the Client retains discretion to allocate or reallocate tasks within these programs as necessary. This flexibility allows for the efficient management and optimization of resources across all projects falling under the Work Scope.",
    "contradiction_score": 0.7693567276000977,
    "kept": true
  },
  {
    "clause_index": 97,
    "start_char": 38073,
    "end_char": 38388,
    "original": "Roche hereby grants to FMI a non-exclusive, royalty-free, worldwide and perpetual license, sublicensable to Affiliates, to use the Roche-Owned Advanced Genomic Analysis Results to develop, make, have made, use, offer for sale, sell, import and commercialize FMI\u2019s products and services relating to genomic analysis.",
    "ollama_generated": "FMI is granted a non-exclusive, worldwide, perpetual, and royalty-free license, with the right to sublicense to its Affiliates, by Roche, for the use of the Advanced Genomic Analysis Results owned by Roche. This license permits FMI to utilize these results solely for the purpose of research and development, without any obligation to commercialize products or services related to genomic analysis derived from such research. However, should FMI choose to commercialize such products or services, it shall be responsible for all costs associated with their production, distribution, and sales.",
    "contradiction_score": 0.0045586456544697285,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 98,
    "start_char": 38388,
    "end_char": 38740,
    "original": "FMI hereby grants to Roche a non-exclusive, royalty-free, worldwide and perpetual license, sublicensable to Roche\u2019s Affiliates under any FMI Improvements for Roche\u2019s internal research purposes and to develop, make, have made, use, offer for sale, sell, import and commercialize Roche\u2019s products and services other than diagnostic products and services.",
    "ollama_generated": "FMI hereby provides to Roche a non-transferable, limited license, not granting exclusive rights, with the understanding that any royalties or fees are due upon request by FMI, for worldwide use, indefinitely, but only within the specified duration of this agreement. This license extends to Roche's Affiliates for the purpose of utilizing FMI Improvements exclusively for their internal research and development endeavors. Roche is granted authorization to produce, procure production from third parties, utilize, market, sell, and commercialize products and services, excluding diagnostic products and services, based on these improvements, subject to FMI's prior approval of any commercialization activities.",
    "contradiction_score": 0.05568943917751312,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 104,
    "start_char": 41913,
    "end_char": 42212,
    "original": "2.1.5 CDx Development Program FMI hereby grants to Roche a non-exclusive license under the FMI CDx IP for internal research purposes, and to the extent necessary to research, develop, make, have made, use, offer for sale, sell, import and commercialize Roche products other than diagnostic products.",
    "ollama_generated": "2.1.5 In regard to the CDx Development Program, FMI hereby grants Roche a non-exclusive, revocable license under the FMI CDx IP for internal research purposes, limited to the scope required for the investigation and development of potential products. Any additional rights, such as the right to produce, use, offer for sale, sell, import, or commercialize these potential products, whether diagnostic or not, will be subject to separate negotiations and agreement between the parties.",
    "contradiction_score": 0.0053675612434744835,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 105,
    "start_char": 42212,
    "end_char": 42771,
    "original": "If FMI is unwilling or unable to develop and commercialize a CDx Assay for a given country in the Territory as specified in the R&D Plan, and on the timeline set forth in the relevant R&D Plan, for any reason other than a breach of this Agreement by Roche, then FMI hereby grants to Roche a non-exclusive, royalty-free, sublicensable, and perpetual license under any intellectual property invented by FMI arising from the CDx Development Program that is necessary for Roche to develop and commercialize a CDx Assay equivalent in such country in the Territory.",
    "ollama_generated": "If, at any point, Roche elects not to proceed with the development and commercialization of a CDx Assay for a given country within the Territory, as outlined in the R&D Plan, due to reasons other than a breach of this Agreement by FMI, then Roche shall be granted a non-exclusive, royalty-free, sublicensable, and perpetual license to utilize any intellectual property owned by FMI that pertains to the CDx Development Program, exclusively for the purpose of creating and marketing an assay equivalent in the specified country within the Territory. The onus is on Roche to initiate this process without undue delay upon making such a decision.",
    "contradiction_score": 0.007580317556858063,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 107,
    "start_char": 43549,
    "end_char": 44232,
    "original": "2.3Right to Subcontract Each Party shall have the right to subcontract the work performed under this Agreement in accordance with the applicable R&D Plan. Each such subcontract with a Third Party shall be pursuant to a written agreement. Each such subcontract by a Party shall include restrictions on the disclosure of the other Party\u2019s Confidential Information that are substantially similar to the protections provided herein. Each Party shall be liable for any action or failure to act by a subcontractor under a subcontract entered into by such Party to the extent such action or failure to act on the part of such Party would constitute a breach of this Agreement by such Party.",
    "ollama_generated": "2.3 Subcontracting Permissions\nEach Party retains the discretion to delegate tasks related to the work specified in this Agreement, in accordance with the relevant R&D Plan. All subcontracts executed with Third Parties must be based on a written understanding. Any subcontract entered into by a Party shall incorporate provisions that safeguard the other Party's Confidential Information to an extent equivalent to the protection accorded herein. The Parties acknowledge and agree that they remain accountable for any actions or omissions committed by their respective subcontractors in the performance of a subcontract, such that if a subcontractor's actions or failures to act would constitute a breach of this Agreement by the Party engaging them, the liable Party shall be held responsible.",
    "contradiction_score": 0.031414695084095,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 110,
    "start_char": 44822,
    "end_char": 45266,
    "original": "3.1.3 Task Orders The Parties will conduct the Molecular Information Platform Program in accordance with agreed upon task orders (\u201c Task Orders \u201d) and in compliance with Performance Specifications and Quality Standards. Each Task Order will be substantially in the form set forth in Appendix 3.1.3. To the extent any terms set forth in a Task Order conflict with the terms set forth in this Agreement, the terms of this Agreement shall control.",
    "ollama_generated": "3.1.3 Task Orders: The Parties shall have the discretion to modify the Molecular Information Platform Program's execution through Task Orders, subject to mutual agreement on performance specifications and quality standards. Each Task Order may deviate from the form provided in Appendix 3.1.3, provided that any conflicting terms in a Task Order will be superseded by those established within this Agreement.\n\nThis revised clause provides more flexibility for both parties to adapt the Molecular Information Platform Program as needed, while maintaining overall agreement guidelines and quality standards. It also emphasizes that any discrepancies between the Task Orders and the main agreement will be resolved in favor of the terms set forth in this Agreement.",
    "contradiction_score": 0.07171859592199326,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 111,
    "start_char": 45266,
    "end_char": 46470,
    "original": "3.1.4 Sample Profiling and Reserved Capacity FMI shall provide, and shall reserve capacity to provide, Roche with comprehensive profiling, analysis and reporting (\u201c Sample Profiling \u201d) of at least [\u2026***\u2026] during the first [\u2026***\u2026] immediately following the Effective date, and at least [\u2026***\u2026] samples during the next [\u2026***\u2026] ***Confidential Treatment Requested*** - 20 - (\u201cReserved Capacity \u201d) using FMI\u2019s platform for molecular genomic profiling of cancer samples (the \u201c Genomic Analysis Platform \u201d). The initial laboratory and computational biology activities performed on the Samples as part of Sample Profiling are \u201c Genomic Analyses \u201d. FMI will provide Sample Profiling in accordance with the Reserved Capacity during the Profiling Term and Profiling Renewal Term, using the then-current versions of the tests included in its Genomic Analysis Platform. The Sampling Profiles shall be provided in a specified format to be mutually agreed by the Parties. The JMC will discuss and decide upon the Reserved Capacity commitment for Profiling Renewal Terms, provided that any Reserved Capacity amount in excess of [\u2026***\u2026] that would require FMI to increase its existing capacity will require FMI approval.",
    "ollama_generated": "3.1.4 Sample Profiling and Minimum Reservation of Capacity: Roche is granted the right to receive, and requests that FMI makes a minimum reservation to provide, comprehensive profiling, analysis, and reporting (\"Sample Profiling\") of no fewer than [***...] samples during the initial period of 20 days following the Effective Date, and at least [***...] samples during each subsequent [***...] period. FMI is not obligated to exceed this minimum reservation unless mutually agreed upon by the Parties. The initial laboratory and computational biology activities performed on the Samples as part of Sample Profiling are termed \"Genomic Analyses.\" FMI shall perform Sample Profiling utilizing its Genomic Analysis Platform, but solely during the periods where it has met its minimum reservation obligations under this clause. Any additional capacity required beyond the minimum reservation will require FMI's approval and may be subject to an increase in FMI\u2019s existing capacity. The Sample Profiles shall be provided in a specified format to be agreed upon by the Parties.",
    "contradiction_score": 0.011499185115098953,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 117,
    "start_char": 49645,
    "end_char": 49927,
    "original": "3.1.7 Clinical Reports FMI will provide Roche with clinical (e.g., FoundationOne\u00ae or FoundationOne\u00ae Heme) reports from Sample Profiling on reasonable request, to be specified in applicable Task Orders, to enable Roche to provide comprehensive information to physicians and patients.",
    "ollama_generated": "3.1.7 Clinical Reports\nRoche shall have the right, upon reasonable notice, to receive clinical reports (e.g., FoundationOne\u00ae or FoundationOne\u00ae Heme) from Sample Profiling provided by FMI for specified Task Orders. These reports will be provided at Roche's discretion and are not obligatorily required for Roche to offer comprehensive information to physicians and patients.",
    "contradiction_score": 0.0039037936367094517,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 118,
    "start_char": 49927,
    "end_char": 50709,
    "original": "3.1.8 Database Insights FMI will provide molecular information insights (\u201c Database Insights \u201d) arising from FMI\u2019s database of aggregated clinical genomic analysis results, which include genomic alterations (base substitutions, insertions and deletions, copy number alterations, and rearrangements) detected by the Genomic Analysis Platform across FMI\u2019s clinical testing experience in all disease ontologies (the \u201c Molecular Information Database \u201d), in response to queries supplied by Roche (\u201c Database Queries \u201d) or generated by FMI in response to discussions between the Parties about areas of interest for Roche (e.g., [\u2026***\u2026]), utilizing a team of [\u2026***\u2026] FMI FTEs with requisite training and experience to generate Database Insights (\u201c Molecular Information Database Access \u201d).",
    "ollama_generated": "3.1.8 Shared Genomic Analysis Results Insights\nRoche shall have access to molecular information insights (\"Shared Genomic Analysis Results\") derived from FMI's database of aggregated clinical genomic analysis results, which encompass genomic alterations (base substitutions, insertions and deletions, copy number alterations, and rearrangements) identified by the Genomic Analysis Platform throughout FMI's clinical testing experience across all disease ontologies (the \"Molecular Information Database\"), upon Roche's provision of queries (\"Database Queries\") or at FMI's discretion, based on mutual discussions about potential areas of interest for Roche (e.g., [...***...]), utilizing a designated team of appropriately trained and experienced FMI employees to generate the Shared Genomic Analysis Results (\"Molecular Information Database Access\"). This provision does not imply any obligation on FMI to actively seek or generate new insights outside of the agreed upon areas of interest, unless otherwise specified in writing by both parties.",
    "contradiction_score": 0.3904709219932556,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 121,
    "start_char": 52001,
    "end_char": 52462,
    "original": "3.1.10 Duration and Extension The term for Sample Profiling set forth in Section 3.1.4 shall commence on the Effective Date and continue for five (5) years thereafter (the \u201cProfiling Term \u201d). The Profiling Term may be extended at Roche\u2019s option, upon [\u2026***\u2026] written notice to FMI as specified in Section 19.13, for additional three (3) year periods, during any period of time in which Roche is a majority shareholder of FMI (each a \u201c Profiling Renewal Term \u201d).",
    "ollama_generated": "3.1.10 Duration and Extension\nThe term for Sample Profiling outlined in Section 3.1.4 shall initiate on the Effective Date and endure for five (5) years subsequent (referred to as the \"Profiling Term\"). FMI may, at its discretion, upon receiving written notice from Roche as described in Section 19.13, extend the Profiling Term by three (3) year periods during any period where FMI holds a majority shareholding by Roche (each such extension is termed a \"Profiling Renewal Term\"). This provision allows for continuous renewal of the Profiling Term as long as Roche maintains its majority ownership in FMI.",
    "contradiction_score": 0.03291524946689606,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 126,
    "start_char": 54756,
    "end_char": 55040,
    "original": "3.2.2 Immuno-Platform Working Group The Parties shall establish the Immuno-Platform Working Group within sixty (60) days after the Effective Date to operationalize the Immunotherapy Testing Platform Development. The Immuno-Platform Working Group\u2019s activities will be overseen by JRDC.",
    "ollama_generated": "3.2.2 Immuno-Platform Working Group: The Parties shall endeavor, though not strictly bound by a fixed timeframe, to form the Immuno-Platform Working Group within a reasonable period following the Effective Date, with the aim of advancing the Immunotherapy Testing Platform Development. While JRDC will provide guidance and oversight for the Immuno-Platform Working Group's activities, ultimate responsibility for its functioning lies with the participating Parties.",
    "contradiction_score": 0.004650353919714689,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 132,
    "start_char": 58249,
    "end_char": 58394,
    "original": "3.2.6 Duration The initial term of the Immunotherapy Testing Platform Development Program will be five (5) years beginning on the Effective Date.",
    "ollama_generated": "3.2.6 Duration: The duration for the implementation of the Immunotherapy Testing Platform Development Program shall commence from the Effective Date and extend for a period of five (5) years, subject to an optional renewal by either party with a written notice of not less than ninety (90) days prior to the expiration of this initial term.",
    "contradiction_score": 0.001906257588416338,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 134,
    "start_char": 59080,
    "end_char": 59673,
    "original": "3.2.8 Exclusivity Except for Excepted Activities, for the lesser of (i) [\u2026***\u2026] after the Effective Date or (ii) [\u2026***\u2026] (the \u201c Immunotherapy Exclusivity Period \u201d), FMI will work exclusively with Roche with respect to [\u2026***\u2026]. Except with regard to Excepted Activities, FMI will not (i) work directly or indirectly with any Third Party in the field of [\u2026***\u2026], (ii) use for the benefit of any Third Party the [\u2026***\u2026] or (iii) transfer to or otherwise enable any Third Party to make use of any data, technology or results from the Immunotherapy Testing Platform Development Program for [\u2026***\u2026].",
    "modified": "3.2.8 Non-Exclusivity: For a duration not exceeding either (i) [...***\u2026] post the Effective Date or (ii) [...***\u2026] (the \"Immunotherapy Exclusivity Period\"), FMI retains the right to engage in activities outside of the scope agreed upon with Roche, related to [...***...]. However, during this period and beyond, FMI reserves the liberty to:\n\n(i) Work directly or indirectly with any Third Party in the field of [...***...], provided such engagement does not interfere with the obligations under this Agreement.\n\n(ii) Utilize the knowledge, data, technology, or results from the Immunotherapy Testing Platform Development Program for purposes other than those specified herein, but only if such use is made solely for FMI's benefit and not for the benefit of any Third Party.\n\n(iii) Transfer to or enable any Third Party to make use of any data, technology, or results from the Immunotherapy Testing Platform Development Program for purposes other than those specified herein, provided that such transfer or enabling does not compromise FMI's obligations under this Agreement.",
    "contradiction_score": 0.9192358255386353,
    "kept": true
  },
  {
    "clause_index": 140,
    "start_char": 60938,
    "end_char": 61178,
    "original": "***Confidential Treatment Requested*** - 25 - The ctDNA Working Group shall serve as a forum for discussion and sharing updates and information between the Parties, but shall have no decision-making authority. The ctDNA Working Group shall:",
    "ollama_generated": "****Limited Decision-Making Authority Granted*** - 25 - The ctDNA Working Group is established as a platform for dialogue and dissemination of updates and knowledge among the Parties, with understanding that it possesses limited decision-making capabilities. In this capacity, the ctDNA Working Group shall:\n\nThis revised clause subtly changes the original by shifting the focus towards the limited authority the group has in making decisions, as opposed to its role in discussing and sharing information, which is maintained. This could potentially result in a more passive role for the ctDNA Working Group in decision-making processes.",
    "contradiction_score": 0.2669033110141754,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 141,
    "start_char": 61178,
    "end_char": 61839,
    "original": "(i) serve as a forum for discussing the development of the ctDNA Platform and ctDNA Products\u037e (ii) serve as a forum for coordinating the Parties\u2019 efforts to carry out the R&D Plan\u037e (iii) periodically monitor progress of activities under the R&D Plan and discuss any obstacles or delays with regard to achieving the timelines set forth therein\u037e (iv) discuss the overall strategy, including the submission plans, for obtaining and maintaining Regulatory Approval of any of the ctDNA Products\u037e and (v) such other responsibilities as may be assigned to the ctDNA Working Group in or pursuant to this Agreement or as may be mutually agreed by the Parties in writing.",
    "ollama_generated": "(i) function as a platform for deliberations on the evolution of the ctDNA Platform and ctDNA Products; (ii) act as a platform for synchronizing the efforts of the Parties to execute the R&D Strategy; (iii) regularly evaluate the advancements in activities under the R&D Strategy and address any potential complications or delays in meeting the outlined timelines; (iv) deliberate on the comprehensive approach, including submission strategies, for securing and maintaining Regulatory Approvals for any of the ctDNA Products; and (v) be assigned additional duties as may be delegated to the ctDNA Working Group under this Agreement or consensually determined by the Parties in written form, with an understanding that these responsibilities are optional and may not be imposed if a Party expresses reluctance.",
    "contradiction_score": 0.0012679623905569315,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 145,
    "start_char": 63470,
    "end_char": 63661,
    "original": "Roche assumes no liability for use of the Genomic Analyses obtained from Samples provided under this Agreement, except as and to the extent arising out of a breach by Roche of this Agreement.",
    "modified": "The User acknowledges that they alone bear full responsibility for any consequences arising from their use of the Genomic Analyses derived from the Samples supplied under this Agreement, with the exception of instances where such consequences stem directly from our (Roche's) breach of this Agreement.",
    "contradiction_score": 0.6706607341766357,
    "kept": true
  },
  {
    "clause_index": 151,
    "start_char": 64661,
    "end_char": 65576,
    "original": "3.4CDx Development Program 3.4.1 Scope Roche and FMI shall conduct the CDx Development Program pursuant to a mutually agreed R&D Plan. The activities conducted in connection with the CDx Development Program will be overseen by the JRDC. The purpose of the CDx Development Program is to develop certain companion diagnostic tests or assays (the \u201c CDx Assays \u201d) for use in connection with certain Roche products. Such CDx Assays may include those developed at Roche\u2019s request in connection with markers that have not yet been approved by the FDA for the particular tumor type/indication for which Roche is developing the relevant therapeutic (\u201c Investigational Markers \u201d) and those developed by mutual agreement of the Parties in connection with markers that are included in one or more assays approved by the FDA for the particular tumor type/indication to indicate use of a Roche therapeutic (\u201c Approved Markers \u201d).",
    "ollama_generated": "3.4CDx Development Program\n\n3.4.1 Scope\nThe Joint Research and Development Committee (JRDC) shall oversee the conduct of the CDx Development Program, in accordance with a mutually agreed R&D Plan between FMI and Roche. The activities under this program will be undertaken by both parties, with Roche primarily responsible for the development of certain companion diagnostic tests or assays (the \"CDx Assays\"). These CDx Assays may encompass those developed at Roche's initiative in relation to markers that are not yet FDA-approved for the relevant tumor type/indication for which the associated therapeutic is being developed (\"Investigational Markers\"), as well as those developed collaboratively by the parties for markers that are included in one or more assays approved by the FDA for the specific tumor type/indication, to indicate the use of a Roche therapeutic (\"Approved Markers\"). In the event that FMI is responsible for developing any CDx Assays related to Investigational Markers, Roche shall provide necessary support and resources.",
    "contradiction_score": 0.06063959747552872,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 155,
    "start_char": 66911,
    "end_char": 67964,
    "original": "3.4.3 R&D Plan The Parties will conduct the CDx Development Program in accordance with the R&D Plan and in compliance with Performance Specifications and Quality Standards. Unless decided otherwise by the JMC, the R&D Plan will be updated [\u2026***\u2026] by the CDx Platform Working Group, reviewed and recommended for approval by the JRDC and approved by the JMC. The R&D Plan will set forth (i) the scope of the CDx Development Program and the resources that will be dedicated to the activities contemplated within the CDx Development Program, including the responsibilities of each Party (ii) specific objectives for each year, which objectives will be updated or amended, as appropriate, by the JRDC as research progresses, and (iii) budgets for such activities. The Parties shall prepare a plan for activities to be conducted no later than [\u2026***\u2026] before the first anniversary of the Effective Date. The JMC shall review the R&D Plan on an ongoing basis and may amend the R&D Plan. Any such changes shall be reflected in written amendments to the R&D Plan.",
    "ollama_generated": "3.4.3 R&D Plan:\nThe conduct of the CDx Development Program will be guided by the R&D Plan, adhering to Performance Specifications and Quality Standards. The JMC reserves the right to decide on any modifications regarding the updating of the R&D Plan. Initially, the R&D Plan will be developed by the CDx Platform Working Group, subject to review and recommendation for approval by the JRDC. However, the final approval rests with the JMC. The R&D Plan will outline (i) the general direction and resources allocated for the CDx Development Program, detailing the roles of each Party, (ii) broad objectives for each year, which may be adjusted or amended as research progresses at the discretion of the JRDC, and (iii) budgets for these activities. It is expected that the Parties will prepare a preliminary plan for activities no later than [...***...] before the first anniversary of the Effective Date. The R&D Plan will be subject to ongoing review by the JMC, with the power to amend the R&D Plan as they deem necessary. Any such changes will be documented in written amendments to the R&D Plan.\n\nThis revised clause weakens the obligation of the Parties to prepare a plan for activities by making it expected rather than required and gives more discretion to the JMC regarding the updating and approval of the R&D Plan, shifting the responsibility for adjusting objectives from the Parties to the JRDC.",
    "contradiction_score": 0.023660460487008095,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 157,
    "start_char": 68671,
    "end_char": 69107,
    "original": "FMI will be responsible for performing the development work for the CDx Assays according to the individual CDx R&D Plans. Unless otherwise expressly agreed between the Parties, FMI will be responsible for seeking regulatory approval (including PMAs, 510(k)s or equivalent) for the CDx Assays. FMI will provide Roche with cross-reference letters, and shall otherwise coordinate regulatory submissions and related information, with Roche.",
    "modified": "In compliance with this agreement, Roche will assume responsibility for seeking regulatory approval (including PMAs, 510(k)s or equivalents) for the CDx Assays, subject to any specific agreements reached between the Parties. FMI shall be responsible for performing the development work according to the individual CDx R&D Plans and will provide Roche with cross-reference letters. Furthermore, FMI will coordinate regulatory submissions and related information, with Roche having the primary role in this process.",
    "contradiction_score": 0.9454438090324402,
    "kept": true
  },
  {
    "clause_index": 160,
    "start_char": 69664,
    "end_char": 69743,
    "original": "3.4.6 Duration The term of the CDx Development Program shall be five (5) years.",
    "modified": "3.4.6 Termination Clause: The CDx Development Program may be terminated by either party after a period of three (3) years, with a notice period of sixty (60) days, unless otherwise agreed in writing by both parties.",
    "contradiction_score": 0.7241227030754089,
    "kept": true
  },
  {
    "clause_index": 161,
    "start_char": 69743,
    "end_char": 70022,
    "original": "3.4.7 Extension Roche shall have the right to extend the term of the CDx Development Program, upon [\u2026***\u2026] prior written notice to FMI as specified in Section 19.13, for additional three (3) year periods, during any period of time in which Roche is a majority shareholder of FMI.",
    "ollama_generated": "3.4.7. Should FMI wish to continue the CDx Development Program beyond its initial term, it shall have the option to do so, subject to Roche's prior written notice as detailed in Section 19.13, for additional three (3) year periods, during any period where Roche maintains a majority ownership of FMI. This provision allows for the program's extension only when Roche remains a majority shareholder, placing the onus on FMI to extend the agreement if and when Roche's ownership status changes.",
    "contradiction_score": 0.006057256367057562,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 171,
    "start_char": 75816,
    "end_char": 75954,
    "original": "4.Diligence Roche and FMI shall use Commercially Reasonable Efforts to perform their respective activities contemplated by this Agreement.",
    "ollama_generated": "4.While endeavoring to adhere to the spirit of this Agreement, Roche and FMI will apply a reasonable business judgment when executing their assigned duties as defined within this Agreement. It should be noted that the application of such judgment does not guarantee successful outcomes or the avoidance of delays.",
    "contradiction_score": 0.0017681393073871732,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 173,
    "start_char": 76744,
    "end_char": 76967,
    "original": "6.Governance 6.1Joint Management Committee Within sixty (60) days after the Effective Date, the Parties shall establish a JMC to ensure the smooth operation of the arrangements and activities envisaged under this Agreement.",
    "modified": "6.Governance 6.1 (Joint Management Committee)\nThe Parties shall make reasonable efforts, within one hundred and twenty (120) days following the Effective Date, to establish a Joint Management Committee for the coordination of activities under this Agreement, with the understanding that delay in its establishment will not significantly impair the smooth operation of the arrangements.",
    "contradiction_score": 0.8171117901802063,
    "kept": true
  },
  {
    "clause_index": 189,
    "start_char": 83821,
    "end_char": 84715,
    "original": "a)recommend the R&D Plans for approval by the JMC\u037e b)review and recommend for approval any revisions to the R&D Plans\u037e ***Confidential Treatment Requested*** - 33 - c)review and oversee the execution of the R&D Plans\u037e d)establish timelines and criteria for decision points\u037e e)determine whether criteria have been met, including whether the criteria as to whether milestones or events have been achieved\u037e f)review the efforts of the Parties and allocate those resources for the R&D Plans (including their budgets)\u037e g)identify appropriate resources necessary to conduct the R&D Plans\u037e h)oversee the progress of the Work Streams\u037e j)monitor the development costs and manage reimbursement for FMI activities under this Agreement\u037e k)determine for Products and Services Performance Specifications and identify Quality Standards applicable to respective Work Streams\u037e l)attempt to resolve any disputes.",
    "ollama_generated": "a) Provide suggestions for the R&D Plans, with the ultimate decision on approval lying with the JMC; b) Examine and propose recommendations for the approval of modifications to the R&D Plans; ***Confidential Treatment Requested*** - 33 - c) Review and supervise the implementation of the R&D Plans, but without direct responsibility for execution; d) Propose timelines and criteria for key decision points; e) Assess whether the proposed criteria have been met, including verification of the achievement of milestones or events; f) Evaluate the collective efforts of the Parties and suggest resource allocations for the R&D Plans (including budgets); g) Recommend suitable resources required to carry out the R&D Plans; h) Oversee the progress of the Work Streams, but with no direct authority over their direction or management; i) Monitor development costs and coordinate reimbursement for FMI activities under this Agreement; j) Determine guidelines for Product and Service Performance Specifications and suggest Quality Standards relevant to each Work Stream; k) Endeavor to resolve any disputes that may arise, but without binding authority.",
    "contradiction_score": 0.004154627211391926,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 198,
    "start_char": 88403,
    "end_char": 88917,
    "original": "8.Payment 8.1FTE Funding Roche will be responsible for funding the FTEs in accordance with the R&D Plans and budgets at the FTE Rate for performance of the research and other activities for which FMI is responsible under the R&D Plans and for the database queries. Each individual included in the funded FTEs shall possess a bachelor\u2019s degree or higher in a relevant scientific discipline and shall be experienced in the type of research or other activities to be performed by such individual under this agreement.",
    "ollama_generated": "8. Reimbursement 8.1FTE Compensation: FMI assumes financial responsibility for the remuneration of the FTEs, in accordance with the R&D Plans and budgets at the FTE Rate, for the execution of the research and other activities for which Roche is responsible under the R&D Plans. The funded FTEs shall have a bachelor\u2019s degree or higher in a relevant scientific discipline and shall possess experience in the type of research or other activities to be performed by such individual under this agreement. Any discrepancies in payment will be addressed by FMI.\n\nIn essence, this clause shifts the responsibility for funding FTEs from Roche to FMI, while keeping the requirements for qualifications and work scope consistent. The change in terminology from \"Payment\" to \"Reimbursement\" and \"Funding\" to \"Compensation\" helps clarify the financial arrangement between the parties.",
    "contradiction_score": 0.35306888818740845,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 199,
    "start_char": 88917,
    "end_char": 89422,
    "original": "8.2Molecular Information Platform Program Fees 8.2.1 Sample Profiling Fees 8.2.1.1Reserved Capacity Fees In consideration for the Reserved Capacity and provision of the Sample Results associated with the Reserved Capacity, and subject to any reduction resulting from the application of Article 5, Roche shall pay to FMI an amount equal to [\u2026***\u2026] for [\u2026***\u2026] of the Profiling Term [\u2026 ***\u2026] for the [\u2026***\u2026] of the Profiling Term (\u201c Reserved Capacity Fees \u201d). The Reserved Capacity Fees are paid as follows:",
    "ollama_generated": "8.2 Molecular Information Platform Program Fees\n  8.2.1 Sample Profiling Fees\n  8.2.1.1 Utilization Charges\n\nIn consideration for the access and utilization of the Reserved Capacity and provision of the Sample Results associated with the utilized capacity, and subject to any increases permitted by Article 5, FMI shall pay to Roche an amount equal to [\u2026***\u2026] for [\u2026***\u2026] of the Profiling Term [\u2026 ***\u2026] for the [\u2026***\u2026] of the Profiling Term (\" Utilization Charges \"). The Utilization Charges are paid as follows:\n\nFMI's payments to Roche shall be made in accordance with the actual utilization of the Reserved Capacity, with any underutilization or excess capacity not being subject to refund. The burden of ensuring that the Reserved Capacity is utilized efficiently lies solely with FMI.",
    "contradiction_score": 0.35885971784591675,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 205,
    "start_char": 90691,
    "end_char": 90818,
    "original": "8.2.1.2Per Sample Profiling Fees The per Sample Profiling fees (notwithstanding the Reserved Capacity Fee) shall be as follows:",
    "ollama_generated": "8.2.1.2 Sample Profiling Fees Exemption: Exempted from the payment of Sample Profiling fees (inclusive of the Reserved Capacity Fee) shall be:\n\nThis revision changes the obligation to pay the per sample profiling fee by exempting the party from that fee, making it weaker.",
    "contradiction_score": 0.07830141484737396,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 207,
    "start_char": 90832,
    "end_char": 91456,
    "original": "8.2.2 Molecular Information Database Access and Database Queries Fees For Molecular Information Database Access and performance of Database Queries by FMI, Roche will pay FMI a total of [\u2026***\u2026] of the Database Term, (the \u201c Database Access Fee \u201d), which is comprised of funding for [\u2026***\u2026] FTEs, each at the FTE Rate, for performance of such Database Queries and delivery of Database Insights, and a Database Access Fee of [\u2026***\u2026]. Roche shall pay to FMI the Database Access Fee [\u2026***\u2026] installments of [\u2026***\u2026], each payable every [\u2026***\u2026] of the Database term and within [\u2026***\u2026] after receipt by Roche of an invoice from FMI.",
    "modified": "8.2.2 Access and Query Fees for Molecular Information Database\n\nFMI will have the right to charge Roche a total of [\u2026***\u2026] throughout the Database Term (the \"Database Access Fee\"), which will cover expenses associated with the maintenance of the required FTEs, each at the FTE Rate, as well as the execution of Database Queries and delivery of Database Insights. The Database Access Fee may be adjusted by FMI based on changes in their operational costs. Payments for the Database Access Fee shall be made by Roche to FMI [\u2026***\u2026] installments of [\u2026***\u2026], each payable at least [\u2026***\u2026] prior to the beginning of each interval and within [\u2026***\u2026] after receipt by Roche of an invoice from FMI. In case of any discrepancies or queries related to the Database Access Fee, Roche will have the responsibility to promptly raise such concerns with FMI for resolution.",
    "contradiction_score": 0.5441545248031616,
    "kept": true
  },
  {
    "clause_index": 209,
    "start_char": 91652,
    "end_char": 91818,
    "original": "Roche will pay FMI [\u2026***\u2026] of FMI Development Cost as agreed in the Immunotherapy Testing Platform Budget for development of the Immuno- Biomarker Discovery Platform.",
    "ollama_generated": "FMI shall be responsible for bearing the proportionate share, as previously determined in the Immunotherapy Testing Platform Budget, towards the costs associated with the development of the Immuno- Biomarker Discovery Platform, and Roche will reimburse FMI accordingly.",
    "contradiction_score": 0.004689070396125317,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 219,
    "start_char": 93625,
    "end_char": 93946,
    "original": "Roche will pay FMI [\u2026***\u2026] if FMI successfully [\u2026***\u2026] set forth in the R&D Plan (\u201c Initial Roche ctDNA Assay \u201d) within [\u2026***\u2026] from [\u2026 ***\u2026] (the \u201c First ctDNA Milestone Date \u201d). Payment by Roche shall be made within [\u2026***\u2026] after achieving the First ctDNA Milestone Date and the receipt by Roche of an invoice from FMI.",
    "ollama_generated": "Should FMI successfully accomplish the Initial Roche ctDNA Assay as specified in the R&D Plan by a date not later than [\u2026***\u2026] from [\u2026 ***\u2026], FMI will be entitled to receive payment from Roche. The payment will become due within [\u2026***\u2026] following the verification of the First ctDNA Milestone Date and upon the submission of a valid invoice from FMI to Roche. This modification places the onus on FMI for requesting and receiving payment, rather than Roche initiating it.",
    "contradiction_score": 0.010323506779968739,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 230,
    "start_char": 95839,
    "end_char": 95847,
    "original": "[\u2026***\u2026].",
    "ollama_generated": "[Upon the occurrence of the aforementioned conditions, it shall be incumbent upon the parties involved to make every reasonable effort to address the matter at hand. However, should such efforts prove unsuccessful, it will not constitute a breach of this agreement and no party shall bear responsibility for any resulting consequences.]\n\nThe original clause imposed an obligation on the parties to resolve an issue; the rewritten clause softens that obligation by stating they must make \"every reasonable effort\" and specifies that failure to resolve the issue does not constitute a breach of the agreement.",
    "contradiction_score": 0.028821615502238274,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 231,
    "start_char": 95847,
    "end_char": 96088,
    "original": "Upon achievement of each of the CDx Assay volumes under this Section 8.5.3, FMI shall timely notify Roche and payment shall be made by Roche within [\u2026***\u2026] after achieving the applicable event and the receipt by Roche of an invoice from FMI.",
    "modified": "Upon fulfillment of each CDx Assay volume under Section 8.5.3, FMI has the discretion to submit an invoice to Roche, following which, Roche will endeavor to process the payment within a reasonable timeframe post receipt of the invoice from FMI. Notification by FMI regarding the achievement of each event is not obligatory under this agreement.",
    "contradiction_score": 0.9529300332069397,
    "kept": true
  },
  {
    "clause_index": 232,
    "start_char": 96088,
    "end_char": 96319,
    "original": "In the event the Parties wish to develop another CDx Assay other than those specified above for [\u2026***\u2026] and [\u2026***\u2026] pursuant to a CDx R&D Plan, the Parties shall mutually agree to [\u2026***\u2026] milestones and payments for achieving them.",
    "ollama_generated": "Should either Party express an interest in creating another CDx Assay beyond those already defined herein, apart from those outlined in a CDx R&D Plan, it will be incumbent upon both Parties to negotiate and agree upon any relevant milestones and associated compensation for their attainment, without such obligations being binding until explicitly agreed upon in writing.",
    "contradiction_score": 0.019562719389796257,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 233,
    "start_char": 96319,
    "end_char": 96947,
    "original": "8.6General Terms All rates and costs set forth herein shall remain firm for the Agreement Term and the services to be performed under each Work Stream, unless otherwise agreed to in writing, shall be at the FTE Rate. FMI has an affirmative obligation to use Commercially Reasonable Efforts to negotiate favorable terms for all FMI Development Cost that will be passed through FMI to Roche. FMI shall extend to Roche the benefit of any and all discounts and savings provided to FMI in connection with FMI Development Cost that will be passed through to Roche. Roche shall [\u2026***\u2026], any amounts in excess of the agreed upon budget.",
    "modified": "8.6 General Terms\nThe rates and expenses stated within this agreement shall remain consistent for the contract duration and the services executed under each Work Stream, unless otherwise consented to in writing. It is understood that FMI shall make reasonable efforts, but not be bound by any specific obligation, to secure advantageous terms for all FMI Development Costs to be passed on to Roche. FMI reserves the right to retain any discounts or savings obtained from FMI Development Costs before passing them on to Roche. In case expenses exceed the predetermined budget, Roche is responsible for covering these excess costs.",
    "contradiction_score": 0.6315303444862366,
    "kept": true
  },
  {
    "clause_index": 237,
    "start_char": 97837,
    "end_char": 97975,
    "original": "9.3Method of Payment All amounts payable hereunder shall be paid in US dollars (the \u201c Payment Currency \u201d) to account(s) designated by FMI.",
    "modified": "9.3 Method of Receipt: All amounts receivable hereunder shall be received in US dollars (the \"Receiving Currency\") at the accounts designated by the Counterparty. The Obligor shall bear any and all exchange rate risks associated with such conversion from the Receiving Currency to any other currency as may be necessary.",
    "contradiction_score": 0.8812333345413208,
    "kept": true
  },
  {
    "clause_index": 240,
    "start_char": 98992,
    "end_char": 99542,
    "original": "***Confidential Treatment Requested*** - 39 - It is understood between the Parties that the agreed upon and/or applied remunerations and other payments under this Agreement for all transactions between (a) FMI and (b) Roche are based on arm\u2019s length and good faith considerations. Should such remunerations for products and services or other payments nevertheless be challenged by any Governmental Authority including any tax authority in the US, or in Switzerland or other jurisdiction of Roche or its relevant Affiliates (\u201c Roche\u2019s Jurisdiction \u201d):",
    "ollama_generated": "****Confidential Treatment Requested*** - 39 - It is mutually acknowledged by the Parties that the remunerations and payments, as defined within this Agreement, for all transactions between (a) FMI and (b) Roche, are established with due regard to arm's length principles and good faith. In the event that these remunerations or payments for products, services, or other considerations receive scrutiny by any Governmental Authority, including but not limited to tax authorities in the US, Switzerland, or any jurisdiction affiliated with Roche (\"Roche's Jurisdiction\"), the burden of proof shall rest upon the challenging party to establish that the initial arrangements were not made in accordance with arm's length principles and good faith.",
    "contradiction_score": 0.004693493712693453,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 242,
    "start_char": 100352,
    "end_char": 101276,
    "original": "(b) In the event that the US tax authorities determine that such remunerations for products and services or other payments are not appropriate and levy an assessment on FMI, and such assessment results in a refund (or similar payment or credit) by or from the tax authorities in Roche\u2019s Jurisdiction to Roche or its relevant Affiliate, then Roche shall pay (or shall ensure that Roche shall pay) the amount of such refund to FMI. In the event that the tax authorities in Roche\u2019s Jurisdiction determine that such remunerations for products and services or other payments are not appropriate and levy an assessment on Roche, and such assessment results in a refund (or similar payment or credit) by or from the US tax authorities to FMI then FMI shall pay (or shall ensure that FMI shall pay) the amount of such refund to Roche. Each Party shall use its reasonable efforts to obtain such refund (or similar payment or credit).",
    "modified": "(b) If, in the discretion of the US tax authorities, they deem that the remunerations for products and services or other payments made to FMI are questionable and impose an assessment on FMI, and such assessment leads to a refund (or equivalent payment or credit) by the tax authorities within Roche's Jurisdiction to Roche or its pertinent Affiliate, then FMI shall be responsible for reimbursing (or ensuring reimbursement of) the amount of such refund to Roche. Conversely, if the tax authorities in Roche\u2019s Jurisdiction find that the remunerations or payments made to Roche are questionable and impose an assessment on Roche, resulting in a refund (or equivalent payment or credit) by the US tax authorities to FMI, then Roche shall not be obligated to make any payment to FMI. Each Party shall exert its reasonable efforts to secure such refund (or equivalent payment or credit). This provision is intended to address potential double recoveries of refunds or payments from the respective tax authorities.",
    "contradiction_score": 0.6231526136398315,
    "kept": true
  },
  {
    "clause_index": 253,
    "start_char": 106908,
    "end_char": 107312,
    "original": "Except as specifically set forth herein, this Agreement shall not be construed, by implication, necessity or otherwise as (i) giving any of the Parties any license, right, title, interest in or ownership to the Confidential Information\u037e (ii) granting any license or right under any intellectual property rights\u037e or (iii) representing any commitment by either Party to enter into any additional agreement.",
    "ollama_generated": "Beyond the express provisions detailed herein, this Agreement is not intended, either implicitly or explicitly, to convey to any of the Parties any license, right, title, interest, or ownership in the Confidential Information; nor does it grant any license or right under any intellectual property rights belonging to either Party. Furthermore, neither Party should be understood to have made any commitment to enter into additional agreements, beyond what is explicitly stated herein.",
    "contradiction_score": 0.003500818507745862,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 254,
    "start_char": 107312,
    "end_char": 107834,
    "original": "12.1.2 For the Molecular Information Platform Program Subject to the license granted to FMI under Section 2.1.2, Roche shall exclusively own all right title and interest to any information, results, and intellectual property from any Clinical Study undertaken or supported by Roche, including, without limitation, the Sample Results and information and results from any Sample Profiling. FMI shall assign to Roche its rights to any intellectual property in or arising from the Sample Results (except for FMI Improvements).",
    "modified": "12.1.2 In relation to the Molecular Information Platform Program, FMI is granted a license as detailed in Section 2.1.2, with the caveat that Roche retains sole ownership of all rights, titles, and interests pertaining to any information, results, or intellectual property stemming from Clinical Studies conducted or sponsored by Roche. This includes, but is not limited to, the Sample Results and data generated from Sample Profiling. Notably, Roche shall be assigned FMI's rights to any intellectual property derived from the Sample Results, except for those improvements that are solely attributed to FMI's efforts.",
    "contradiction_score": 0.9467179179191589,
    "kept": true
  },
  {
    "clause_index": 259,
    "start_char": 109411,
    "end_char": 109862,
    "original": "To the extent third-party intellectual property must be licensed for the Immunotherapy Testing Platform Development, Roche and FMI shall jointly decide on an appropriate in-licensing strategy and negotiate a fair cost sharing between the Parties in good faith\u037e provided however, that FMI shall retain the right to take such a license at its own cost on such terms as it shall determine if the Parties cannot reach a timely agreement on how to proceed.",
    "ollama_generated": "In relation to any necessary licensing of third-party intellectual property for the development of the Immunotherapy Testing Platform, Roche and FMI will collaborate in selecting an acceptable in-licensing approach, aiming to establish equitable cost distribution between the parties in good faith. Notably, if a mutually agreeable course of action is not reached within a reasonable timeframe, FMI reserves the authority to secure such a license independently at its own expense and on terms it deems suitable.",
    "contradiction_score": 0.001098860870115459,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 261,
    "start_char": 110257,
    "end_char": 110486,
    "original": "12.1.5 For the CDx Development Program Subject to the license granted to Roche under Section 2.1.5, FMI shall exclusively own all intellectual property arising from the CDx Development that Covers the CDx Assays (\u201c FMI CDx IP \u201d).",
    "modified": "12.1.5 In relation to the CDx Development Program, and with acknowledgment of the license granted to Roche under Section 2.1.5, the parties hereby agree that any intellectual property generated from the CDx Development relating to the CDx Assays (\"CDx IP\") shall be jointly owned by FMI and Roche (\"Joint CDx IP\"). Each party retains the right to use, develop, and commercialize the Joint CDx IP independently, subject to their respective obligations under this Agreement.",
    "contradiction_score": 0.9508813619613647,
    "kept": true
  },
  {
    "clause_index": 265,
    "start_char": 111916,
    "end_char": 113341,
    "original": "12.3Prosecution and Maintenance of Patent Rights Claiming FMI Inventions FMI shall, at its own expense and discretion, (i) control and Handle all FMI Foreground Patent Rights, (ii) consult with Roche as to the Handling of such FMI Foreground Patent Rights, and (iii) furnish to Roche copies of all material documents relevant to any such Handling. FMI shall furnish such documents and consult with Roche in sufficient time before any action by FMI is due to allow Roche to provide comments thereon, which comments FMI must consider. At FMI\u2019s - 43 - expense and reasonable request, Roche shall cooperate, in all reasonable ways with the Handling of all FMI Foreground Patent Rights. If FMI elects not to Handle any FMI Foreground Patent Rights under this Section 12.3, then FMI shall provide at least [\u2026***\u2026] prior written notice to Roche. Thereafter, Roche shall have the right, but not the obligation to Handle any such notified FMI Foreground Patent Rights, at its sole expense and its sole discretion. Notwithstanding the foregoing, and for clarity, FMI shall have no obligations to Roche under this Section 12.3 in regard to FMI Foreground Patent Rights relating to the Genomic Analysis Platform or the Molecular Information Database (including, without limitation, methods, procedures, and algorithms related to or embodied in each) that do not incorporate or rely on the continued use of Roche Confidential Information.",
    "ollama_generated": "12.3 Responsibility for Patent Rights Claiming FMI Inventions:\n\nRoche shall have the right, but not the obligation, at its sole expense and discretion, (i) to control and handle all Roche Foreground Patent Rights pertaining to FMI inventions, (ii) to consult with FMI regarding the handling of such Roche Foreground Patent Rights, and (iii) to receive copies of all material documents relevant to any such handling. Roche shall provide its comments on these documents in a timely manner, which FMI is obligated to consider. Upon FMI's reasonable request, and at no additional cost, FMI shall cooperate, in all reasonable ways, with the handling of all Roche Foreground Patent Rights. If Roche elects not to handle any Roche Foreground Patent Rights under this Section 12.3, it shall provide at least [\u2026***\u2026] prior written notice to FMI. Thereafter, FMI shall have the right, but not the obligation, to handle any such notified Roche Foreground Patent Rights, at its sole expense and its sole discretion. Notwithstanding the foregoing, for clarity, Roche shall have no obligations to FMI under this Section 12.3 in regard to Roche Foreground Patent Rights relating to the Genomic Analysis Platform or the Molecular Information Database (including, without limitation, methods, procedures, and algorithms related to or embodied in each) that do not involve the disclosure or use of FMI Confidential Information.",
    "contradiction_score": 0.25900378823280334,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 273,
    "start_char": 117059,
    "end_char": 117635,
    "original": "If for a Joint Patent Right, Roche decides to bring a suit or take action, once Roche provides Suit Notice, Roche may immediately commence such suit or take such action. In the event that Roche (i) does not in writing advise FMI within the Decision Period that Roche will commence suit or take action, or (ii) fails to commence suit or take action within a reasonable time after providing Suit Notice, FMI shall thereafter have the right to commence suit or take action in the Territory and shall provide written notice Roche of any such suit commenced or action taken by FMI.",
    "ollama_generated": "If a Joint Patent Right arises, it is incumbent upon FMI to be notified, in writing, within the Decision Period if Roche elects to initiate legal proceedings or actions (referred to as Suit Notice). Should Roche choose not to proceed with such action, or delay doing so beyond a reasonable timeframe after providing the notice, FMI retains the authority to instigate suitable legal proceedings or actions within the Territory. Upon taking such steps, FMI is obligated to promptly inform Roche in writing of any initiated suit or action.",
    "contradiction_score": 0.04488417133688927,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 284,
    "start_char": 124237,
    "end_char": 126559,
    "original": "(a) it has all requisite power and authority to enter into and perform its obligations under this Agreement\u037e (b) it has no outstanding agreement or obligation that is in conflict with any of the provisions of this Agreement or that would preclude its personnel from complying with the provisions hereof\u037e (c) all of its employees, officers and consultants have executed agreements requiring assignment to it of all Inventions made by such individuals during the course of and as a result of their participation in activities under this Agreement\u037e (d) the execution, delivery and performance of this Agreement by it and all instruments and documents to be delivered by it hereunder: (i) are within its corporate power\u037e (ii) have been duly authorized by all necessary or proper corporate action\u037e (iii) are not in contravention of any provision of any of its formation or governing documents\u037e (iv) to its knowledge, will not violate any law or regulation or any order or decree of any court of governmental instrumentality\u037e (v) will not violate the terms of any indenture, mortgage, deed of trust, lease, agreement, or other instrument to which it is a party or by which it or any of its property is bound, which violation would have an adverse effect on its financial condition or on its ability to perform its obligations hereunder\u037e and (vi) do not require any filing or registration with, or the consent or approval of, any governmental body, agency, authority or any other person, which has not been made or obtained previously (other than approvals required under the HSR Act, Regulatory Approvals required for the sale of Products and filings with Regulatory Authorities required in connection with Products)\u037e (e) there are no claims or investigations (other than with respect to the Parties\u2019 HSR filings), pending or threatened against it or any of its Affiliates, at law or in equity, or before or by any governmental authority relating to the matters contemplated under this Agreement or that would materially adversely affect its ability to perform its obligations hereunder\u037e and (f) neither it nor any of its Affiliates is or will be under any obligation to any person, contractual or otherwise, that is conflicting with the terms of this Agreement or that would impede the fulfillment of its obligations hereunder.",
    "ollama_generated": "(a) It possesses all necessary power and authority to execute and abide by its commitments under this Agreement; (b) There are no existing agreements or obligations it holds that contradict any provisions within this Agreement, or hinder its personnel from adhering to the terms herein; (c) All employees, officers, and consultants have agreed, in writing, to assign to it all Inventions created during their involvement with activities under this Agreement; (d) The execution, delivery, and performance of this Agreement by it, along with any related instruments and documents:\n\n   (i) Are within the scope of its corporate power;\n   (ii) Have been properly authorized through all necessary corporate procedures;\n   (iii) Do not breach any provisions found in its formation or governing documents;\n   (iv) To the best of its knowledge, will not infringe any law, regulation, court order, or governmental decree;\n   (v) Will not contravene the terms of any indenture, mortgage, deed of trust, lease, agreement, or other instrument to which it is a party, or by which it or its property is bound. Any such violation would significantly impact its financial status or capacity to meet its contractual obligations; (vi) Do not necessitate any filing or registration with, or the consent or approval of, any governmental body, agency, authority, or individual, unless such has already been completed previously (other than approvals required under the HSR Act, Regulatory Approvals necessary for the sale of Products, and filings with Regulatory Authorities in relation to Products);\n   (vii) There are no pending or impending claims or investigations (other than those related to the Parties\u2019 HSR filings) at law or in equity, or before any governmental authority concerning matters relevant to this Agreement, that would materially hinder its performance of its obligations hereunder; (h) Neither it nor any of its Affiliates is currently subject to, or will become subject to, any obligation to any person, contractual or otherwise, which conflicts with the provisions of this Agreement, or impedes the fulfillment of its responsibilities under this Agreement.",
    "contradiction_score": 0.004255102481693029,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 287,
    "start_char": 127069,
    "end_char": 127331,
    "original": "13.4Third Party Patent Rights FMI represents and warrants that FMI has no knowledge of the existence of any patent or patent application owned by or licensed to any Third Party that could prevent in the Territory the activities contemplated under this Agreement.",
    "ollama_generated": "13.4 Regarding Third-Party Patent Rights, FMI acknowledges and represents that it has no awareness of any patents or patent applications owned by, or licensed to, any Third Party within the Territory, but does not provide assurance that such rights do not exist. FMI disclaims any responsibility for identifying potential patent conflicts arising from Third-Party Patent Rights which may restrict activities as per this Agreement.",
    "contradiction_score": 0.005601273849606514,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 309,
    "start_char": 138394,
    "end_char": 138710,
    "original": "16.2Permitted Disclosure Notwithstanding the obligation of non-use and non-disclosure set forth in Section 16.1, the Parties recognize the need for certain exceptions to this obligation, specifically set forth below, with respect to press releases, patent rights, publications, and certain commercial considerations.",
    "ollama_generated": "16.2 Exceptions to Confidentiality Obligation: Although the Parties are bound by the confidentiality obligations outlined in Section 16.1, they acknowledge that there may be instances where disclosure is necessary and permissible. Such instances shall include, but not be limited to, press releases, patent rights filings, publications, and commercial dealings necessitated by the parties' mutual interests.",
    "contradiction_score": 0.0031263127457350492,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 315,
    "start_char": 142009,
    "end_char": 144508,
    "original": "17.2Termination 17.2.1 Termination for Breach A Party (\u201c Non-Breaching Party \u201d) shall have the right to terminate this Agreement on a Work Stream-by-Work Stream basis, or, for Roche, on an Approved Marker or Investigational Marker basis in the case of the CDx Development Program, in the event the other Party (\u201c Breaching Party \u201d) is in material breach of any of its material obligations under the applicable Work Stream (or obligations pertaining to an Approved Marker or Investigational Marker program). Failure of FMI to comply materially with Performance Specifications or Quality Standards shall be considered a material breach by FMI. For avoidance of doubt, a Non-Breaching Party shall only be permitted to terminate the Work Stream (or Approved Marker or Investigational Marker program) to which a material breach of a material obligation relates. The Non-Breaching Party shall provide written notice to the Breaching Party, which notice shall identify the breach. Except in the event of a breach that, by its nature, is not amenable to cure, in which case termination may be made effective immediately, the Breaching Party shall have a period of [\u2026***\u2026] after such written notice is provided (\u201cPeremptory Notice Period \u201d) to cure such breach or, absent withdrawal of the Non-Breaching Party\u2019s request for termination, the relevant Work Stream (or Approved Marker or Investigational Marker program) shall terminate\u037e provided that, if the Breaching Party has a  bona fide  dispute as to whether such breach: (i) occurred, (ii) pertains to a material obligation, or (iii) has been cured, the Breaching Party will so notify the Non-Breaching Party, the relevant Work Stream (or Approved Marker or Investigational Marker program) shall not terminate and the expiration of the Peremptory Notice Period shall be tolled until such dispute is resolved pursuant to Section 19.2. If such dispute is resolved by finding that the Non-Breaching Party is entitled to terminate the relevant Work Stream (or Approved Marker or Investigational Marker program), the Breaching Party may have the remainder of the Peremptory Notice Period to cure such breach. If such breach is not cured within the Peremptory Notice Period, then absent withdrawal of the Non-Breaching Party\u2019s request for termination, the relevant Work Stream (or Approved Marker or Investigational Marker program) shall terminate in accordance with the notice from the Non-Breaching Party as of the expiration of the Peremptory Notice Period.",
    "ollama_generated": "17.2 Termination and Cure Period\n\n17.2.1 Termination for Breach: The Breaching Party shall be given an opportunity to remedy any material breach of its obligations under this Agreement, unless the nature of the breach is such that it cannot be cured, in which case termination may occur immediately. The Non-Breaching Party reserves the right to terminate this Agreement on a Work Stream-by-Work Stream basis, or, for Roche, on an Approved Marker or Investigational Marker basis in the case of the CDx Development Program, if the Breaching Party is found in material breach of its obligations. Any failure by FMI to comply materially with Performance Specifications or Quality Standards shall be deemed a material breach.\n\nFor clarification, the Non-Breaching Party's right to terminate shall extend only to the Work Stream (or Approved Marker or Investigational Marker program) where the material breach occurred. The Breaching Party shall receive written notice of the breach from the Non-Breaching Party, which notice will specify the breach in question.\n\nUpon receipt of such notice, the Breaching Party will have a period of [***] days (\"Cure Period\") to rectify the breach. If the Breaching Party disputes whether the breach has occurred, pertains to a material obligation, or has been remedied, it may notify the Non-Breaching Party and the Cure Period will be extended until the dispute is resolved in accordance with Section 19.2. If the dispute resolution process finds that the Breaching Party is not in breach, the Agreement shall continue in full force and effect.\n\nIf the Breaching Party does not cure the breach within the Cure Period, or if the dispute resolution process determines that a material breach has occurred, then the relevant Work Stream (or Approved Marker or Investigational Marker program) shall terminate automatically at the end of the Cure Period, unless the Non-Breaching Party withdraws its request for termination.",
    "contradiction_score": 0.032131094485521317,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 323,
    "start_char": 148924,
    "end_char": 150613,
    "original": "a.In the event of termination of the Molecular Information Platform Program Work Stream, Roche shall pay FMI all [\u2026 ***\u2026] that would be owed over the remainder of the Agreement Term, or any [\u2026***\u2026], plus any applicable incremental per Sample Profiling Fees for Sample Profiling performed by FMI during the year in which termination occurs that are [\u2026***\u2026]\u037e b.In the event of termination of the Immunotherapy Testing Platform Development Work Stream, (1) for avoidance of doubt, Roche shall pay FMI Roche\u2019s share of any FMI Development Costs incurred in connection with the Immunotherapy Testing Platform Development Work Stream as of the effective date of termination that were not previously paid by Roche\u037e (2) (A) if the effective date of termination occurs prior to FMI\u2019s completion of the Immuno- Biomarker Discovery Platform, then Roche will pay FMI for the entirety of the FMI Development Costs FMI incurred in connection with FMI\u2019s performance of the Immunotherapy Testing Platform Development Work Stream, excluding any portion that was previously paid by Roche, or (B) if the effective date of termination occurs after FMI\u2019s commencement of Signature Identification services, then Roche will pay FMI for the entirety of the FMI Development Costs FMI incurred prior to the effective date of termination in connection with any ongoing performance of Signature Identification work by FMI, excluding any portion of such FMI Development Costs that was previously paid by Roche or that is payable by Roche under the foregoing clause (1)\u037e and (3) Roche shall pay FMI in accordance with Section 8.3.2 with respect to signatures developed by FMI prior to the effective date of termination.",
    "ollama_generated": "a.Upon the termination of either the Molecular Information Platform Program Work Stream or the Immunotherapy Testing Platform Development Work Stream, FMI shall be entitled to receive all outstanding payments owed for the remainder of the Agreement Term, or any amounts still due, plus any applicable incremental per Sample Profiling Fees for Sample Profiling performed by FMI during the year in which such termination takes place, unless otherwise specified. Additionally, FMI will not be obligated to complete any further work on said Work Streams once terminated. b.In the event that either of the aforementioned Work Streams is terminated: (1) Roche shall reimburse FMI for its share of any unpaid FMI Development Costs incurred up until the effective date of termination in connection with the Immunotherapy Testing Platform Development Work Stream. (2) If the termination occurs prior to FMI's completion of the Immuno- Biomarker Discovery Platform, Roche will be responsible for paying FMI the full amount of unpaid FMI Development Costs related to its performance on the Immunotherapy Testing Platform Development Work Stream, excluding any portion previously paid by Roche. (3) If the termination takes place after FMI's commencement of Signature Identification services, Roche will pay FMI for the full amount of unpaid FMI Development Costs incurred up until the effective date of termination related to its ongoing performance of Signature Identification work, excluding any portion previously paid by Roche or payable under this clause (1) or as otherwise specified. In all cases, Roche will comply with Section 8.3.2 regarding signatures developed by FMI prior to the effective date of termination.\n\nThis version of the clause slightly modifies the original by shifting some obligations from FMI to Roche, clarifying that FMI is not obligated to complete any further work once a Work Stream has been terminated, and making it clearer that any unpaid development costs will be paid by Roche up until the effective date of termination.",
    "contradiction_score": 0.3093138635158539,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 326,
    "start_char": 152806,
    "end_char": 153089,
    "original": "For avoidance of doubt, in the event FMI terminates the Agreement in its entirety due to Roche\u2019s Insolvency, all Work Streams and other activities under the Agreement will be deemed to be terminated and all of the applicable effects of termination in this Section 17.3.2 shall apply.",
    "ollama_generated": "To eliminate any potential confusion, should FMI opt to discontinue the Agreement entirely as a result of Roche's financial instability (Insolvency), it will be understood that all Work Streams and related tasks under the Agreement will simultaneously conclude. Consequently, the effects outlined in Section 17.3.2 regarding termination shall be triggered, with FMI bearing no further obligations or liabilities beyond this point, unless otherwise specified in the Agreement.",
    "contradiction_score": 0.0013299996498972178,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 330,
    "start_char": 154914,
    "end_char": 155501,
    "original": "17.3.4 Direct License Irrespective of anything to the contrary in this Agreement, any existing, permitted sublicense granted by a Party under this Agreement (and any further sublicenses thereunder) shall, upon a termination of the license granted hereunder that pertains to such sublicense, shall terminate\u037e provided that if the licensee Party so requests in writing, the licensor Party shall negotiate with the relevant sublicensee towards the grant of a direct license of rights, provided that such sublicensee is not then in breach of its sublicense agreement with the licensee Party.",
    "ollama_generated": "17.3.4 Direct License Notwithstanding any provisions to the contrary within this Agreement, any granted sub-licenses, whether current or allowed under this contract (and any subsequent ones arising from them), will automatically terminate upon the revocation of the primary license relevant to such sub-license, unless explicitly requested otherwise in writing by the licensee Party. However, it is important to note that the onus is on the licensor Party to negotiate in good faith with the respective sub-licensee towards the establishment of a direct licensing arrangement, should they not currently be in violation of their sub-license agreement with the licensee Party. This provision does not obligate the licensor Party to grant such direct license but rather encourages a spirit of mutual cooperation and understanding.",
    "contradiction_score": 0.00265340693295002,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 335,
    "start_char": 157807,
    "end_char": 158161,
    "original": "19.2Disputes Unless otherwise set forth in this Agreement, in the event of any dispute in connection with this Agreement, such dispute shall be referred to the respective executive officers of the Parties designated below or their designees, for good faith negotiations attempting to resolve the dispute. The designated executive officers are as follows:",
    "ollama_generated": "19.2 Disputes: Except as otherwise specified within this Agreement, in case any disagreements arise concerning this Agreement, such disputes will be handled initially by non-binding mediation between the appointed executive officers of each Party or their delegates. The Parties appoint the following executive officers for this purpose:\n\nThe designated executive officers are as follows:",
    "contradiction_score": 0.056458283215761185,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 336,
    "start_char": 158161,
    "end_char": 158629,
    "original": "For FMI: CEO Roche:Head of Roche Partnering 19.3Arbitration Should the Parties fail to agree within [\u2026***\u2026] after such dispute has first arisen, it shall be finally settled by arbitration in accordance with the Rules of American Arbitration Association  (\u201cAAA\u201d)  as in force at the time when initiating the arbitration. The tribunal shall consist of three arbitrators. The place of arbitration shall be New York, New York, US. The language to be used shall be English.",
    "modified": "In the event that a disagreement arises between the Parties and remains unresolved after a period of [***...] from its initial emergence, the responsibility for settling the dispute lies exclusively with arbitration, governed by the American Arbitration Association's (AAA) rules as they are at the commencement of the arbitration process. The tribunal will be composed of a sole arbitrator appointed by the AAA. The location for this arbitration shall be New York, New York, US. The language to be utilized throughout the proceedings shall be English.\n\nIn essence, we have shifted the composition of the arbitration panel from three arbitrators to a single arbitrator appointed by the AAA, potentially simplifying the arbitration process and reducing costs associated with multiple arbitrators.",
    "contradiction_score": 0.7644588351249695,
    "kept": true
  },
  {
    "clause_index": 340,
    "start_char": 159857,
    "end_char": 160046,
    "original": "Any Party-appointed arbitrator or the third arbitrator resigns or ceases to be able to act, a replacement shall be appointed in accordance with the arrangements provided for in this clause.",
    "ollama_generated": "In the event that any Party-designated arbitrator becomes unable or unwilling to fulfill their duties, or is disqualified, it will be incumbent upon the remaining Parties to agree on a suitable replacement, in accordance with the procedure outlined within this clause. If they fail to reach an accord, the appointing authority identified in this agreement shall be responsible for selecting and appointing the new arbitrator.",
    "contradiction_score": 0.03869960457086563,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 347,
    "start_char": 161908,
    "end_char": 162553,
    "original": "Any arbitration proceeding hereunder shall be confidential and the arbitrators shall issue appropriate protective orders to safeguard each Party\u2019s Confidential Information. Except as required by law, neither Party shall make (or instruct the arbitrators to make) any public announcement with respect to the proceedings or decision of the arbitrators without prior written consent of the other Party. The existence of any dispute submitted to arbitration, and the award, shall be kept in confidence by the Parties and the arbitrators, except as required in connection with the enforcement of such award or as otherwise required by Applicable Law.",
    "ollama_generated": "Any arbitration proceedings hereunder will maintain discretionary confidentiality, and while the parties retain the right to petition for protective orders to safeguard their Confidential Information, they shall do so at their sole discretion. The parties acknowledge that any disclosure of information related to the proceedings or decisions of the arbitrators may occur under applicable law without prior written consent of the other party. However, each party is encouraged to maintain a level of confidentiality regarding the existence of any dispute submitted to arbitration, as well as the resulting award, unless compelled by law in connection with the enforcement of such award or otherwise required by Applicable Law.",
    "contradiction_score": 0.048539742827415466,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 351,
    "start_char": 163421,
    "end_char": 164304,
    "original": "19.5Debarment and Exclusion 19.5.1 Past Activities Each Party represents and warrants that it has never been debarred under 21 U.S.C. \u00a7335a, disqualified under 21 C.F.R. \u00a7312.70 or \u00a7812.119, sanctioned by a Federal Health Care - 59 - Program (as defined in 42 U.S.C \u00a71320 a-7b(f)), including without limitation the federal Medicare or a state Medicaid program, or debarred, suspended, excluded or otherwise declared ineligible from any other similar Federal or state agency or program. In the event a Party receives notice of debarment, suspension, sanction, exclusion, ineligibility or disqualification under the above-referenced statutes, such Party shall immediately notify the other Party in writing and such other Party shall have the right, but not the obligation, to terminate this Agreement, effective, at such other Party\u2019s option, immediately or at a specified future date.",
    "ollama_generated": "19.5 Debarment and Exclusion\n\n19.5.1 Past Activities Each Party assures that it has not been subjected to any debarment under 21 U.S.C. \u00a7335a, disqualification under 21 C.F.R. \u00a7312.70 or \u00a7812.119, sanction by a Federal Health Care Program (as defined in 42 U.S.C \u00a71320 a-7b(f)), including but not limited to the federal Medicare or a state Medicaid program, or debarred, suspended, excluded, or deemed ineligible from any other similar Federal or state agency or program. In the event a Party becomes aware of potential debarment, suspension, sanction, exclusion, ineligibility, or disqualification under the aforementioned statutes, it is obligated to promptly inform the other Party in writing. Upon receipt of such notice, the other Party retains the discretionary right, not the obligation, to elect whether to terminate this Agreement, effective immediately or at a future date selected by the exercising party.",
    "contradiction_score": 0.01337344478815794,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 358,
    "start_char": 167213,
    "end_char": 167376,
    "original": "19.11Amendments No amendments of the terms and conditions of this Agreement shall be binding upon either Party hereto unless in writing and signed by both Parties.",
    "ollama_generated": "19.11 Modifications: Any proposed modifications to the terms and conditions of this Agreement must be made in writing, signed by a duly authorized representative of each Party, and shall only become effective upon mutual agreement by both Parties in writing.",
    "contradiction_score": 0.0019160708179697394,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 360,
    "start_char": 167558,
    "end_char": 168022,
    "original": "F. Hoffmann-La Roche Ltd Kreditorenbuchhaltung 4070 Basel Switzerland 19.13Notice All notices that are required or permitted hereunder shall be in writing and sufficient if delivered personally, sent by facsimile (and promptly confirmed by personal delivery, registered or certified mail or overnight courier), sent by nationally recognized overnight courier or sent by registered or certified mail, postage prepaid, return receipt requested, addressed as follows:",
    "ollama_generated": "G. Notice Provisions:\nAll notices that are required or permitted under this agreement shall be in writing and considered sufficient if delivered electronically, confirmed immediately via personal delivery, email, or telephone call, or sent by nationally recognized overnight courier or registered mail, return receipt requested, postage prepaid, addressed as follows:\n\nRecipient's Name\n[Recipient's Address]\nCity, State, ZIP Code\nCountry\n\nEmail: [Recipient's Email Address]\nTelephone: [Recipient's Telephone Number]\n\nFor purposes of this agreement, electronic delivery shall be deemed to have been received upon confirmation of successful transmission. Any other delivery method is only considered delivered when confirmed by a written or electronic acknowledgment of receipt from the recipient.",
    "contradiction_score": 0.20223209261894226,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 371,
    "start_char": 169852,
    "end_char": 169932,
    "original": "B.Schedule  \u2013 Task start date, projected end date and checkpoint dates (if any).",
    "modified": "C.Scheduling Provisions - Anticipated commencement date, estimated completion date, and potential milestone dates (where applicable).\n\nExplanation: The original clause specifies definite start, end, and checkpoint dates for a task or project. The revised clause subtly softens this requirement by using the word \"anticipated\" instead of \"definite,\" signifying that while there will be an estimated timeline, it may not be strictly adhered to. Additionally, the phrase \"potential milestone dates\" implies that these may or may not occur depending on various factors. The clause also shifts responsibility from explicitly stating the checkpoint dates (B) to merely indicating their potential existence (C).",
    "contradiction_score": 0.5588546395301819,
    "kept": true
  }
]